<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <meta name="generator"
    content="HTML Tidy for FreeBSD (vers 1st April 2002), see www.w3.org" />
    <base
    href="http://www.cirp.org/library/treatment/BXO/meffert1/" />
    <meta name="robots" content="index, follow" />
    <meta name="author" content="Julie Shearer" />
    <meta name="keywords"
    content="Jeffrey Meffert, Brian Davis, Ronald Grimwood, lichen sclerosus, LS, LSA, lichen sclerosus et atrophicus, Hallopeau, White Spot Disease, balanitis, BXO, kraurosis vulvae, lichen planus, LP, atrophy, leukoplakia, scleroderma, ichthyosis, corticosteroids, retinoids, dyspareunia, stenosis, labial fusion, phimosis, pruritis, dysuria, Koebner phenomenon, isomorphic phenomenon, borrelia, fibrosis, hyperkeratosis, vaginal dystrophy, hyperplastic dystrophy, vulvodynia, neurodermatitis, leukoplakic vulvitis, hyperplastic vulvitis, lichenoid infiltrate, morphea" />
    <meta name="Description"
    content="Article on the history of diagnosis and treatment of lichen sclerosus." />
    <meta name="description"
    content="A medical journal article." />

    <title>Lichen Sclerosus</title>

    <script type="text/javascript" language="JavaScript">
    //<![CDATA[
// bust out of a frame
<!-- hide
var caught = 0;
if (top.frames.length != 0) {
  caught++;
  if (caught != 0)
  {
    top.location=self.document.location;
  }
}
// end hide -->
    //]]>
    </script>
    <style type="text/css">
/*<![CDATA[*/
<!--
body 
{
background-color: white;
color: black;
}
div.corpus
{
margin-left: 10%;
margin-right: 10%;
}
h2
{
font-family: arial, helvetica;
}
p.cirp
{
text-align: center;
font-weight: bold;
color: navy;
}
p.navlink
{
text-align: center;
}
span.yellow
{
background-color: #ff9;
}
p.library
{
font-size: 13pt;
text-align: center;
font-family: "times new roman", times, serif;
font-weight: bold;
}
span.sclibrary
{
font-size: 10pt;
}
-->
/*]]>*/
    </style>
  </head>

  <body bgcolor="white">
    <p class="library">T<span class="sclibrary">HE</span> C<span
    class="sclibrary">IRCUMCISION</span> R<span
    class="sclibrary">EFERENCE</span> L<span
    class="sclibrary">IBRARY</span></p>
    <hr size="1" color="black" />

    <h3>JOURNAL OF THE AMERICAN JOURNAL OF DERMATOLOGY, Volume 32,
    Number 3: Pages 393-416,<br />
     March 1995</h3>
    <br />
    <br />

    <center>
      <h2>Lichen Sclerosus</h2>
    </center>

    <div class="corpus">
      <center>
        <p><a id="top" name="top"></a><b><font
        face="Arial,Helvetica">Jeffrey J. Meffert, Brian M. Davis,
        and Ronald E. Grimwood.</font></b></p>
      </center>

      <p><font face="Arial"><font size="-1">Lichen sclerosus,
      usually appearing in the dermatologic literature under the
      names of lichen sclerosus et atrophicus, balanitis xerotica
      obliterans, and kraurosis vulvae, is an inflammatory disease
      with a multifactorial origin. A past association of lichen
      sclerosus and genital squamous cell carcinoma is not as close
      as once thought. Once considered primarily a surgical
      problem, especially when the genitals are involved, lichen
      sclerosus will respond to a variety of systemic and topical
      therapies.</font></font></p>

      <p class="cirp">[CIRP Note: The figures supplied with the
      article are not included in this file.]</p>

      <p><font size="+0">Lichen sclerosus (LS), usually reported in
      the dermatologic literature as lichen sclerosus et
      atrophicus, is an inflammatory disease of unknown cause and
      incompletely characterized pathogenesis. Beginning with the
      initial case reports at the turn of the century, there has
      been much confusion in the literature because of the plethora
      of terms used to describe LS. Different names have been
      applied depending on the lesional location and the specialty
      of the author. More than 15 years ago, gynecologists
      standardized the terminology used in reporting vulvar
      dystrophies, including LS. Because the majority of reported
      cases of LS involve the female genitalia and because of the
      multiplicity of synonyms for LS one of the factors that makes
      the body of LS-related literature less accessible, we
      recommend that the gynecologists' term <i>lichen
      sclerosus</i> be used in future reports of LS, lichen
      sclerosus et atrophicus, and balanitis xerotica obliterans
      (BXO). Interest in LS remains high because of the pervasive,
      erroneous concept that LS itself is a premalignant
      condition.</font></p>

      <p><b><font face="Arial,Helvetica">HISTORY</font></b><br />
       <font size="+0">&nbsp;&nbsp;&nbsp; Hallopeau is usually
      credited with the first clinical description of what was to
      be later called lichen sclerosus et atrophicus. In 1887 he
      described a patient with coalescent papules on the trunk and
      forearms who also had pruritis and lichenification of the
      vulva.</font><sup><a href="#FN1"><font
      size="-1">1</font></a></sup><font size="+0">However, in 1875
      Weir described a patient with vulvar and oral "ichthyosis"
      and provided an excellent clinical description of LS,
      possibly the first published case of this
      disease.</font><sup><a href="#FN2"><font
      size="-1">2</font></a></sup><font size="+0">During the next
      11 years Hallopeau described three more cases of what he
      believed to be a unique form of atrophic lichen
      planus.</font><sup><a href="#FN3"><font
      size="-1">3-5</font></a></sup><font
      size="+0">Darier</font><sup><a href="#FN6"><font
      size="-1">6</font></a></sup><font size="+0">commented on
      Hallopeau's original case, but it was not until 1892 that
      Darier</font><sup><a href="#FN7"><font
      size="-1">7</font></a></sup><font size="+0">formally
      described the typical histological features of LS. In the
      decades after Hallopeau's description many noteworthy
      independent observers "discovered" LS and applied their own
      names to what, in retrospect, was clinically and
      histologically the same disease. Some of the more frequent
      and widely published early synonyms for LS include lichen
      plan atrophique (Hallopeau,</font><sup><a href="#FN1"><font
      size="-1">1</font></a></sup><font size="+0">1887), lichen
      plan scl&eacute;reux (Darier,</font><sup><a href="#FN7"><font
      size="-1">7</font></a></sup><font size="+0">1892),
      Kartenblattf&ouml;rmige Sklerodermie ("playing card" or
      "cardboard-like" scleroderma; Unna,</font><sup><a
      href="#FN8"><font size="-1">8</font></a></sup><font
      size="+0">1894), Weissflecken Dermatose ("white spot
      disease"; Westberg,</font><sup><a href="#FN9"><font
      size="-1">9</font></a></sup><font size="+0">1901), lichen
      albus (von Zumbusch,</font> <sup><a href="#FN10"><font
      size="-1">10</font></a></sup><font size="+0">, 1901), lichen
      planus sclerosus et atrophicus (Montgomery and
      Ormsby,</font><sup><a href="#FN11"><font
      size="-1">11</font></a></sup><font size="+0">1907),
      dermatitis lichenoides chronica atrophicans
      (Csillag,</font><sup><a href="#FN12"><font
      size="-1">12</font></a></sup><font size="+0">1909), kraurosis
      vulvae (Breisky,</font><sup><a href="#FN13"><font
      size="-1">13</font></a></sup><font size="+0">1885), and
      balanitis xerotica obliterans (St&uuml;hmer,</font><sup><a
      href="#FN14"><font size="-1">14</font></a></sup><font
      size="+0">1928).</font><br />
       <font size="+0">&nbsp;&nbsp;&nbsp; Much of the world
      literature on LS is confounded with other entities under such
      terms as circumscribed scleroderma, leukoplakic vulvitis,
      primary atrophic vulvitis, atrophic and bullous lichen
      planus, acrodermatitis chronica atrophicans, and bullous
      scleroderma. Although most of the dermatologic literature
      reports "lichen sclerosus et atrophicus," the shortened
      "lichen sclerosus" has appeared sporadically since the 1920s.
      However, Friedrich</font><sup><a href="#FN15"><font
      size="-1">15</font></a></sup><font size="+0">in 1976 argued
      that LS was more "dystrophic" than "atrophic." "Lichen
      sclerosus" was formally adopted by the International Society
      for the Study of Vulvar Disease</font><sup><a
      href="#FN16"><font size="-1">16</font></a></sup><font
      size="+0">and "et atrophicus" was abandoned in the
      gynecologic literature. In accordance with this
      standardization in nomenclature, the term <i>lichen
      sclerosus</i> will be used unless it is unclear that all data
      and opinions in some older reports refer exclusively to LS
      and not a blend of LS and other disease entities (often the
      case in discussions of "leukoplakia" and
      "kraurosis").</font><br />
       <font size="+0">&nbsp;&nbsp;&nbsp; The controversy about the
      relation of LS to lichen planus (LP) and scleroderma began
      early and continues to this day. Hallopeau believed that LS
      is a form of LP because of occasional oral
      findings.</font><sup><a href="#FN17"><font
      size="-1">17</font></a></sup><font size="+0">Others counter
      with the histologic features of oral lesions so typical of LS
      that the existence of "oral LS" is recognized</font><sup><a
      href="#FN18"><font size="-1">18-25</font></a></sup><font
      size="+0">even as the sole manifestation.</font><sup><a
      href="#FN26"><font size="-1">26</font></a></sup><font
      size="+0">Until recently, some authors still argued for a
      close relation of LS with LP, proposing that if enough
      sections were cut in a biopsy specimen, typical LP would be
      found.</font><sup><a href="#FN27"><font
      size="-1">27</font></a></sup><font size="+0">Others, while
      accepting LS as a distinct entity, suggest that Hallopeau's
      original cases were really atrophic LP.</font><sup><a
      href="#FN17"><font size="-1">17</font></a></sup><font
      size="+0">Although most recent reports do not link LS and LP
      except as coincidental findings, the association of LS and
      morphea (localized scleroderma) remains a topic of research
      and debate and will be discussed in detail
      later.</font><br />
       <font size="+0">&nbsp;&nbsp;&nbsp; Divisive to the
      establishment of consistent principles of diagnosis and
      treatment was the parallel work on the nature and therapy of
      different medical disciplines. The gynecologic literature
      predates Hallopeau with Breisky's description of "kraurosis
      vulvae" in 1885.</font><sup><a href="#FN13"><font
      size="-1">13</font></a></sup><font size="+0">The urologic
      literature dates back to St&uuml;hmer's
      description</font><sup><a href="#FN14"><font
      size="-1">14</font></a></sup><font size="+0">of balanitis
      xerotica obliterans in 1928. Ormsby and
      Mitchell</font><sup><a href="#FN28"><font
      size="-1">28</font></a></sup><font size="+0">first connected
      LS with kraurosis vulvae in 1920, and Freeman and
      Laymon,</font><sup><a href="#FN29"><font
      size="-1">29,30</font></a></sup><font size="+0">made the same
      association with balanitis xerotica obliterans in
      1941.</font> <a href="#Table1">Table I</a> <font
      size="+0">chronicles key events leading to our current
      understanding of LS.</font></p>
      <hr noshade="noshade" width="90%" />
      <b><font face="Arial"><font size="+0">Table 1:<a id="Table1"
      name="Table1"></a> Significant events in the history of
      LS</font></font></b><br />
       &nbsp; 

      <table summary="" border="0" width="80%">
        <tr>
          <td><b>Year</b></td>

          <td><b>Event</b></td>

          <td><b>Key reference no.(s)</b></td>
        </tr>

        <tr>
          <td>1875</td>

          <td>Weir's report of possible vulvar and/or oral LS as
          "ichthyosis"</td>

          <td>2&nbsp;</td>
        </tr>

        <tr>
          <td>1885</td>

          <td>Breisky describes kraurosis vulvae</td>

          <td>13</td>
        </tr>

        <tr>
          <td>1887</td>

          <td>Hallopeau describes series of extragenital LS (and
          one possible vulvar case)</td>

          <td>1, 3-5</td>
        </tr>

        <tr>
          <td>1892</td>

          <td>Darier formally describes classic histopathology of
          LS</td>

          <td>6, 7</td>
        </tr>

        <tr>
          <td>1900-present&nbsp;</td>

          <td>Concept that scleroderma and LS are closely
          related</td>

          <td>72, 73, 222, 227, 231, 290, 358</td>
        </tr>

        <tr>
          <td>1901</td>

          <td>Pediatric LS described</td>

          <td>9, 53, 95, 96, 101, 103</td>
        </tr>

        <tr>
          <td>1913-present&nbsp;</td>

          <td>Concept that scleroderma is <i>not</i> closely
          related to LS</td>

          <td>45, 145, 148, 158, 238, 240, 281</td>
        </tr>

        <tr>
          <td>1920</td>

          <td>Taussig establishes vulvectomy as treatment of choice
          for kraurosis vulvae, a premalignant condition</td>

          <td>93, 183-185; also 79, 186, 191, 196</td>
        </tr>

        <tr>
          <td>1927</td>

          <td>Kyrle defines LS ("white spot disease") as entity sui
          generis</td>

          <td>359</td>
        </tr>

        <tr>
          <td>1928</td>

          <td>St&uuml;hmer describes balanitis xerotica obliterans
          as postcircumcision phenomenon</td>

          <td>14</td>
        </tr>

        <tr>
          <td>1936</td>

          <td>Retinoids (vitamin A) used in LS</td>

          <td>47, 195, 341, 349, 352, 353</td>
        </tr>

        <tr>
          <td>1945</td>

          <td>Testosterone used in genital LS</td>

          <td>87, 92, 160, 254, 337, 338, 342</td>
        </tr>

        <tr>
          <td>1961</td>

          <td>Modern use of corticosteroids</td>

          <td>21, 102, 165, 254, 337, 338, 342</td>
        </tr>

        <tr>
          <td>1966</td>

          <td>Jeffcoate presents argument against vulvectomy for
          simple LS</td>

          <td>119; also 51, 198, 209</td>
        </tr>

        <tr>
          <td>1971</td>

          <td>Progesterone used in LS</td>

          <td>254, 338, 344, 345</td>
        </tr>

        <tr>
          <td>1971</td>

          <td>Wallace defines clinical factors and epidemiology of
          LS for all later reports</td>

          <td>21</td>
        </tr>

        <tr>
          <td>1976</td>

          <td>Friedrich defines LS as a dystrophic, not atrophic
          condition; "et atrophicus" dropped</td>

          <td>15</td>
        </tr>

        <tr>
          <td>1976</td>

          <td>International Society for Study of Vulvar Disease
          classification system. "Kraurosis" and "leukoplakia" no
          longer to be used</td>

          <td>16, 181, 182</td>
        </tr>

        <tr>
          <td>1980</td>

          <td>Fluourinated and superpotent steroids used in LS</td>

          <td>54, 56, 96, 101-103, 254</td>
        </tr>

        <tr>
          <td>1981</td>

          <td>Studies into HLA serotypes and LS</td>

          <td>44, 217, 273, 275-77, 279</td>
        </tr>

        <tr>
          <td>1984</td>

          <td>Etretinate and acetretin used in LS</td>

          <td>25, 149, 343, 354-357</td>
        </tr>

        <tr>
          <td>1987</td>

          <td>LS linked with <i>Borrelia</i> infection</td>

          <td>232, 233, 256, 289, 290</td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <p><b><font face="Arial,Helvetica">CLINICAL
      PRESENTATION</font></b><br />
       <font size="+0">&nbsp;&nbsp;&nbsp; LS can affect all age
      groups with reported onset from 6 months of age to late
      adulthood.</font><sup><font size="-1"><a
      href="#FN21">21,</a><a
      href="#FN31">31,32</a></font></sup><font size="+0">Most
      patients described in the literature are Caucasian, but the
      fact that most studies come out of Great Britain and the
      United States may create a reporting bias. LS has been
      reported in native Africans,</font><sup><a href="#FN33"><font
      size="-1">33,34</font></a></sup><font size="+0">Oriental
      patients,</font><sup><a href="#FN35"><font
      size="-1">35</font></a></sup><font size="+0">and other
      dark-skinned patients.</font><sup><a href="#FN36"><font
      size="-1">36-41</font></a></sup><font size="+0">The majority
      are women, but that reflects the intensive study of vulvar
      "leukoplakia" over the years. The reported female-to-male
      ranges from nearly 10:1,</font><sup><a href="#FN42"><font
      size="-1">42,43</font></a></sup><font size="+0">to nearer
      5:1,</font><sup><font size="-1"><a href="#FN21">21,</a> <a
      href="#FN44">44-47</a></font></sup><font size="+0">to about
      1:1.</font><sup><a href="#FN48"><font
      size="-1">48,49</font></a></sup><font size="+0">More cases of
      purely genital involvement are reported than purely
      non-genital. However, firm epidemiological data are lacking
      for many reasons. Gynecologists and urologists do not
      generally perform a complete cutaneous examination, and
      dermatologists often exclude a genital examination.
      Furthermore, an anatomic definition of what constitutes
      "vulvar" versus "perineal" versus "genital" versus "groin" is
      lacking.</font><sup><a href="#FN50"><font
      size="-1">50</font></a></sup><a href="#Table2">Table II</a>
      summarizes cases known or suspected to be LS.</p>
      <hr noshade="noshade" width="90%" />
      <b><font face="Arial"><font size="+0">Table 2:<a id="Table2"
      name="Table2"></a> A review of LS
      cases</font></font></b><sup><a href="#FN1"><font
      size="-1">1-377</font></a></sup><b><font face="Arial"><font
      size="+0">(<i>N</i> = 5207)</font></font></b><br />
       &nbsp; 

      <table summary="" border="0" width="80%">
        <tr>
          <td><b>Sex</b></td>

          <td>
          </td>

          <td>
          </td>
        </tr>

        <tr>
          <td>Female</td>

          <td>4280&nbsp;</td>

          <td>
          </td>
        </tr>

        <tr>
          <td>Male</td>

          <td>691</td>

          <td>
          </td>
        </tr>

        <tr>
          <td>Unspecified</td>

          <td>236</td>

          <td>Demographics in metabolic studies often not
          specified.</td>
        </tr>

        <tr>
          <td><b>Location</b></td>

          <td>
          </td>

          <td>
          </td>
        </tr>

        <tr>
          <td>Genital</td>

          <td>4308</td>

          <td>Includes labial, perineal, perianal, and any penile
          location.</td>
        </tr>

        <tr>
          <td>Extragential</td>

          <td>805</td>

          <td>Neck, shoulders, upper trunk most common sites
          reported.</td>
        </tr>

        <tr>
          <td>Both</td>

          <td>355</td>

          <td>Excludes cases in which site is uncertain.</td>
        </tr>

        <tr>
          <td><b>Associated Factors</b></td>

          <td>
          </td>

          <td>
          </td>
        </tr>

        <tr>
          <td>Cancer</td>

          <td>283</td>

          <td>Almost all are SCC of the vulva. Includes unknown
          number of other vulvar dystrophies.</td>
        </tr>

        <tr>
          <td>Autoimmune disease</td>

          <td>291</td>

          <td>Not always reported or sought. Thyroid disease,
          vitiligo, diabetes, and pernicious anemia most
          common.</td>
        </tr>

        <tr>
          <td>Autoantibodies</td>

          <td>316</td>

          <td>Not always reported or sought. Thyroid
          antimicrosomal, gastric parietal cell, and antinuclear
          autobodies most common.</td>
        </tr>
      </table>

      <p><b><font size="-1">Data expressed as total number of LS
      cases within each category. <i>SCC,</i> Squamous cell
      carcinoma.</font></b></p>
      <hr noshade="noshade" width="90%" />

      <p>&nbsp;&nbsp;&nbsp; In women, prepubertal, perimenopausal,
      and postmenopausal vulvar and perineal involvement are most
      common. Symptoms include pruritis, burning pain, dyspareunia,
      dysuria, vaginal discharge, anal or genital
      bleeding,<sup><font size="-1"><a href="#FN41">41,</a> <a
      href="#FN51">51,52</a></font></sup> labial stenosis or
      fusion,<sup><a href="#FN53"><font
      size="-1">53,54</font></a></sup> and, especially in children,
      constipation.<sup><a href="#FN55"><font
      size="-1">55,56</font></a></sup> Most cases reported in men
      occur on the glans penis and/or prepuce in prepubertal boys
      and middle-aged men. Male symptoms include sudden phimosis in
      a previously retractable foreskin,<sup><a href="#FN57"><font
      size="-1">57</font></a></sup> adhesions to the glans,<sup><a
      href="#FN29"><font size="-1">29</font></a></sup> decreased
      sensation on the glans, painful erections, meatal stenosis,
      dysuria, urethral discharge, and urinary obstruction.<sup><a
      href="#FN58"><font size="-1">58-61</font></a></sup>
      Ulceration of the glans can occur, even after
      circumcision.<sup><font size="-1"><a href="#FN21">21,</a><a
      href="#FN52">52</a></font></sup><br />
       &nbsp;&nbsp;&nbsp; Extragenital LS is most common on the
      neck and shoulders and is generally asymptomatic in both
      sexes. Pruritis occasionally occurs. Less common
      presentations include infraorbital LS,<sup><a
      href="#FN62"><font size="-1">62</font></a></sup> scarring
      alopecia,<sup><a href="#FN63"><font
      size="-1">63</font></a></sup> involvement of the palms and/or
      soles,<sup><a href="#FN64"><font
      size="-1">64-68</font></a></sup> appearance in
      acrochordons,<sup><a href="#FN69"><font
      size="-1">69</font></a></sup> or on the scrotum.<sup><a
      href="#FN70"><font size="-1">70</font></a></sup> The latter
      is surprisingly rare considering the frequency of genital
      labial involvement.<sup><a href="#FN71"><font
      size="-1">71,72</font></a></sup> Borda et al.<sup><a
      href="#FN73"><font size="-1">73</font></a></sup> proposes a
      "vitiligoid" variant in which pigmentary changes exist
      without papules and plaques. Oral LS is usually
      asymptomatic,<sup><a href="#FN18"><font
      size="-1">18</font></a></sup> although not invariably.<sup><a
      href="#FN22"><font size="-1">22</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Typically, the eruption of LS begins as
      white, polygonal papules that coalesce into plaques. The
      appearance of being "splashed with whitewash" (<a
      href="#fig1">Fig. 1</a>) led to the early appellation of
      "white spot scleroderma."<sup><a href="#FN74"><font
      size="-1">74</font></a></sup> Characteristic are comedo-like
      plugs or evenly spaced dells (<a href="#Fig2">Fig. 2</a>) in
      the surface of the plaque that correspond to appendageal
      ostia. The grouping of dells in coalescent papules has been
      described as cribriform or corymbiform.<sup><a
      href="#FN75"><font size="-1">75</font></a></sup> The plugs
      and dells may disappear with time as the lesion ages, leaving
      a smooth, often porcelain-white plaque. Milia may
      occasionally be apparent.<sup><a href="#FN76"><font
      size="-1">76</font></a></sup> Early LS may have a vesicular
      component,<sup><a href="#FN77"><font
      size="-1">77</font></a></sup> and early genital LS may be
      characterized by edema of the clitoral foreskin<sup><a
      href="#FN78"><font size="-1">78</font></a></sup> as well as
      labial telangiectases and purpura.<sup><a href="#FN21"><font
      size="-1">21</font></a></sup> Fissuring may occur in the
      perineal midline and other intertriginous areas.<sup><a
      href="#FN79"><font size="-1">79</font></a></sup> Bullous LS,
      often accompanied by intralesional hemorrhage,<sup><font
      size="-1"><a href="#FN73">73,</a><a
      href="#FN80">80-82</a></font></sup> may be localized or
      generalized.<sup><a href="#FN83"><font
      size="-1">83-86</font></a></sup> The frenulum may be
      obliterated,<sup><a href="#FN87"><font
      size="-1">87,88</font></a></sup> and the glans may have a
      mottled appearance (<a href="#Fig3">Fig. 3</a>). A sclerotic
      white ring at the preputial opening is diagnostic.<sup><font
      size="-1"><a href="#FN57">57,</a><a
      href="#FN88">88-90</a></font></sup> Late LS has been
      described as "verrucous" on the elbows<sup><a
      href="#FN91"><font size="-1">91</font></a></sup> and other
      sites<sup><font size="-1"><a href="#FN24">24,</a> <a
      href="#FN73">73</a></font></sup> and "hyperkeratotic" on the
      knees.<sup><a href="#FN40"><font
      size="-1">40</font></a></sup> However, such findings in a
      genital location would suggest other dystrophic or infectious
      diseases. Late LS in women is characterized by obliteration
      of the labia minora and periclitoral structures.<sup><font
      size="-1"><a href="#FN21">21,</a><a
      href="#FN92">92</a></font></sup> Many terms are used to
      describe the involvement of labial, perineal, and anal areas,
      including "figure-8,"<sup><a href="#FN55"><font
      size="-1">55</font></a></sup> "keyhole,"<sup><a
      href="#FN55"><font size="-1">55</font></a></sup>
      "hourglass,"<sup><a href="#FN93"><font
      size="-1">93,94</font></a></sup> and the more poetic
      "butterfly" and "lotus flower"<sup><a href="#FN92"><font
      size="-1">92</font></a></sup> (<a href="#Fig4">Fig.
      4</a>).</p>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="fig1" name="fig1"></a><b>Figure 1:</b>
          Extragenital lichen sclerosus, gross morphology.</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig2" name="Fig2"></a><b>Figure 2:</b>
          Extragenital lichen sclerosus.</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig3" name="Fig3"></a><b>Figure 3:</b> Male
          genital lichen sclerosus. Irregular mottling of
          glans.</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig4" name="Fig4"></a><b>Figure 4:</b> Female
          genital lichen sclerosus (early). "Figure-8" dystrophy
          with fusion of clitoral hood, and obliteration of labia
          minora.</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />
      <br />
       LS in children is histologically identical to that in
      adults.<sup><a href="#FN55"><font
      size="-1">55</font></a></sup> However, it represents a
      special subset of LS for several reasons. Ten percent to 15%
      of LS cases occur in children, the majority of which involve
      the female genitalia.<sup><a href="#FN52"><font
      size="-1">52</font></a></sup> Again, the incidence is
      uncertain because of delay or failure to diagnose LS, masking
      of LS by secondary changes,<sup><a href="#FN95"><font
      size="-1">95</font></a></sup> a tendency for spontaneous
      involution, and a reluctance to seek medical care for what
      may be perceived as child sexual abuse.<sup><a
      href="#FN96"><font size="-1">96</font></a></sup> Because of
      the traumatic appearance of hemorrhagic and bullous LS, it is
      discussed in the pediatric literature as an entity often
      confused with sexual abuse.<sup><font size="-1"><a
      href="#FN21">21,</a> <a href="#FN97">97-103</a></font></sup>
      However, it cannot be assumed that the diagnosis of LS
      excludes sexual abuse. In a 7-year-old girl initial
      improvement with treatment was followed by dramatic worsening
      and subsequent confirmation of sexual abuse.<sup><a
      href="#FN104"><font size="-1">104</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; At least half of the cases of genital LS
      in girls will involute by menarche,<sup><font size="-1"><a
      href="#FN21">21,</a> <a
      href="#FN105">105,106</a></font></sup> and the earlier the
      onset of LS, the more likely the resolution.<sup><a
      href="#FN43"><font size="-1">43</font></a></sup> However, not
      all will resolve,<sup><font size="-1"><a
      href="#FN101">101,</a><a href="#FN107">107</a></font></sup>
      and despite "resolution," scarring and pigmentary changes may
      persist.<sup><font size="-1"><a href="#FN21">21,</a><a
      href="#FN52">52,</a><a href="#FN56">56,</a><a
      href="#FN105">105,</a><a href="#FN108">108</a></font></sup>
      Many women with LS will recall childhood symptoms of
      pruritis. However, it is unclear whether LS in these women
      represents persistence, recurrence, or is unrelated to this
      history.<sup><font size="-1"><a href="#FN21">21,</a><a
      href="#FN103">103</a></font></sup> Extragenital involvement
      may<sup><a href="#FN43"><font size="-1">43</font></a></sup>
      or may not<sup><a href="#FN96"><font
      size="-1">96</font></a></sup> be predictive of resolution.
      Spontaneous resolution, when it occurs, is attributed to a
      changing hormonal milieu and increasing endogenous androgen
      levels. However, because most patients also receive at least
      symptomatic therapy, few resolutions are truly
      "spontaneous."<br />
      <br />
       

      <p><b><font face="Arial"><font size="+0">LS AND THE
      ISOMORPHIC PHENOMENON</font></font></b><br />
       &nbsp;&nbsp;&nbsp; LS exhibits the isomorphic or "Koebner"
      phenomenon. <font size="+0">St&uuml;hmer</font><sup><a
      href="#FN14"><font size="-1">14</font></a></sup> and
      Madden<sup><a href="#FN109"><font
      size="-1">109</font></a></sup> considered circumcision the
      cause of LS of the glans penis. However, most believe that
      trauma or chronic infection in the uncircumcised state leads
      to LS.<sup><font size="-1"><a href="#FN58">58,</a><a
      href="#FN110">110,111</a></font></sup> LS has appeared on the
      penis after surgery for squamous cell carcinoma<sup><a
      href="#FN112"><font size="-1">112</font></a></sup> and after
      correction of genital abnormalities in a case of gonadal
      dysgenesis.<sup><a href="#FN113"><font
      size="-1">113</font></a></sup> Bale et al.<sup><a
      href="#FN114"><font size="-1">114</font></a></sup> described
      seven boys in whom LS developed after surgery to correct
      hypospadias.<br />
       &nbsp;&nbsp;&nbsp; The isomorphic phenomenon may also
      contribute to vulvar LS.<sup><a href="#FN115"><font
      size="-1">115</font></a></sup> Inciting factors include
      "warmth and moisture,"<sup><a href="#FN116"><font
      size="-1">116</font></a></sup>low-grade infections including
      pinworms,<sup><font size="-1"><a href="#FN95">95,</a><a
      href="#FN106">106,</a><a
      href="#FN117">117,118</a></font></sup> "tight" or nylon
      underwear,<sup><a href="#FN119"><font
      size="-1">119</font></a></sup> trauma from bicycle
      riding,<sup><a href="#FN55"><font
      size="-1">55</font></a></sup> superficial radiation therapy
      for pruritis,<sup><a href="#FN120"><font
      size="-1">120</font></a></sup> or repeated
      masturbation.<sup><a href="#FN121"><font
      size="-1">121</font></a></sup> Postoperative "Koebnerization"
      is often cited as a reason for the high recurrence rate after
      vulvectomy to treat LS.<sup><font size="-1"><a
      href="#FN51">51,</a><a
      href="#FN122">122,123</a></font></sup><br />
       &nbsp;&nbsp;&nbsp; LS may also appear in extragenital
      surgical sites,<sup><font size="-1"><a href="#FN53">53,</a><a
      href="#FN80">80,</a><a href="#FN124">124</a></font></sup>
      such as cholecystectomy<sup><font size="-1"><a
      href="#FN69">69,</a><a href="#FN125">125</a></font></sup> and
      other surgical scars.<sup><a href="#FN126"><font
      size="-1">126-128</font></a></sup> In two patients LS of the
      trunk occurred after radiation therapy for breast cancer as
      much as 8 years later.<sup><a href="#FN129"><font
      size="-1">129</font></a></sup> Solar radiation and sunburn
      were reported to induce LS in at least 3 patients.<sup><font
      size="-1"><a href="#FN34">34,</a><a href="#FN43">43,</a><a
      href="#FN130">130</a></font></sup> LS appeared at the site of
      old scald burns decades later in another patient.<sup><a
      href="#FN131"><font size="-1">131</font></a></sup> One case
      involved elbow plaques of LS believed to be caused by trauma
      and rubbing.<sup><a href="#FN132"><font
      size="-1">132</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; The concept that friction from clothing
      may cause LS has been advanced several times, for example,
      brassiere straps suspected of causing subclinical shoulder
      trauma eventuating in LS.<sup><a href="#FN133"><font
      size="-1">133,134</font></a></sup> In fact, most LS cases
      reported in the early dermatologic literature, including
      Hallopeau's, occurred on the back and shoulders.<sup><a
      href="#FN135"><font size="-1">135,136</font></a></sup> The
      contribution of solar radiation in these cases in unknown.
      Friction as the stimulus of the isomorphic phenomenon is not
      confined to irritation by external agents. Many consider the
      trauma of skin rubbing against skin the ultimate trigger of
      genital and extragenital LS.<sup><font size="-1"><a
      href="#FN69">69,</a><a href="#FN125">125,</a><a
      href="#FN137">137</a></font></sup><br />
      <br />
      </p>

      <p><b><font face="Arial"><font size="+0">HISTOLOGIC
      CHARACTERISTICS</font></font></b><br />
       &nbsp;&nbsp;&nbsp; The characteristic histologic features of
      LS is critical in identifying cases reported under other
      names. Although variations exist because of lesion duration,
      the overall appearance is surprisingly consistent despite
      differences in patient age and lesion location.<sup><a
      href="#FN138"><font size="-1">138-141</font></a></sup> A
      compact orthohyperkeratosis usually underlies a markedly
      thinned epidermis. The hyperkeratosis usually overlies a
      markedly thinned epidermis. The hyperkeratosis may be such
      that the stratum corneum is thicker than the remainder of the
      epidermis (<a href="#Fig5">Fig. 5</a>). Vacuolar degeneration
      of the basal layer is usual, especially in earlier lesions.
      When extensive, it may cause bulla formation (<a
      href="#Fig6">Fig. 6</a>). Acanthosis, unless it is a part of
      a superimposed lichen simplex chronicus,<sup><a
      href="#FN139"><font size="-1">139,140</font></a></sup> is not
      a feature of LS, nor is cellular atypia.<sup><a
      href="#FN142"><font size="-1">142,143</font></a></sup> These
      findings in genital lesions suggest a hyperplastic or mixed
      dystrophy that may have malignant potential. Follicular
      occlusion by a cornified plug earlier in the course may
      eventuate in atrophy and disappearance of appendageal
      surfaces, including apocrine glands<sup><a
      href="#FN144"><font size="-1">144</font></a></sup> (<a
      href="#Fig7">Fig. 7</a>). Most striking are the morphologic
      changes in the papillary dermis that becomes homogenized and
      edematous early and hyalinized and sclerotic later (<a
      href="#Fig8">Fig. 8</a>). The superficial vascular plexus is
      pushed deeper so that it appears to be in the mid
      dermis.<sup><a href="#FN140"><font
      size="-1">140</font></a></sup><br />
      </p>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig5" name="Fig5"></a><b>Figure 5:</b> Lichen
          sclerosus. Compact hyperkeratosis thicker than effaced
          epidermis. Clefting and hemorrhage within homogenized
          papillary dermis. (Original maginification, X125).</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig6" name="Fig6"></a><b>Figure 6:</b> Lichen
          sclerosus. Lichenoid infiltrate and dilated vessels
          underlying a hemorrhagic subepidermal bulla. (Original
          magnification, X125.)</td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig7" name="Fig7"></a><b>Figure
          7:&nbsp;</b></td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />

      <table summary="" width="80%">
        <tr valign="top">
          <td><a id="Fig8" name="Fig8"></a><b>Figure
          8:&nbsp;</b></td>
        </tr>

        <tr>
          <td>&nbsp;<i>(to be added when I can get the journal out
          of the library)</i></td>
        </tr>
      </table>
      <hr noshade="noshade" width="90%" />
      <br />
       &nbsp;&nbsp;&nbsp; Investigation into the nature of the
      papillary dermal changes may provide clues to the cause of
      LS. Wallace<sup><a href="#FN21"><font
      size="-1">21</font></a></sup> did not believe special stains
      were particularly helpful. However, others have used special
      stains and techniques to define the pathologic changes more
      accurately. Increased ground substance<sup><a
      href="#FN145"><font size="-1">145,146</font></a></sup>
      composed of neutral<sup><a href="#FN147"><font
      size="-1">147</font></a></sup> and acid<sup><a
      href="#FN139"><font size="-1">139</font></a></sup>
      mucopolysaccharides is evident in the edematous papillary
      dermis. Most agree the elastic tissue of the papillary dermis
      degenerates to the point of complete absence in some
      cases.<sup><font size="-1"><a href="#FN22">22,</a> <a
      href="#FN53">53,</a><a href="#FN105">105,</a><a
      href="#FN148">148-152</a></font></sup> However, Mann and
      Cowan<sup><a href="#FN153"><font
      size="-1">153</font></a></sup> found normal to increased
      amounts of elastin in an ultrastructural examination of
      extragenital LS. They conjectured that elastin was modified
      so as to stain poorly with orcein. Other ultrastructural
      studies have shown both degeneration of subepidermal elastin
      and changes in collagen.<sup><font size="-1"><a
      href="#FN95">95,</a><a href="#FN138">138,</a><a
      href="#FN146">146,</a><a href="#FN148">148,</a><a
      href="#FN154">154,155</a></font></sup> Type IV collagen and
      basement membrane itself become fragmented;<sup><font
      size="-1"><a href="#FN95">95,</a><a href="#FN114">114,</a><a
      href="#FN145">145,146,</a><a
      href="#FN154">154</a></font></sup> focal thickening of
      reduplicated basement membrane can also be seen.<sup><font
      size="-1"><a href="#FN147">147,</a><a
      href="#FN153">153</a></font></sup> In the papillary dermis
      collagen types I and III show variation in fiber diameter and
      gross alterations in alignment progressing to disintegration
      and eventual loss.<sup><font size="-1"><a
      href="#FN139">139,</a><a href="#FN149">149</a></font></sup>
      Evidence of collagen regeneration is seen in treated
      LS.<sup><a href="#FN149"><font size="-1">149</font></a></sup>
      Microscopic evidence is of an active collagen degeneration
      and regeneration cycle in static and untreated LS belies the
      old appellation "atrophicus."<sup><font size="-1"><a
      href="#FN95">95,</a><a href="#FN138">138,</a><a
      href="#FN146">146,</a><a
      href="#FN153">153-155</a>&nbsp;</font></sup> This cycle of
      destruction and regeneration causes sclerosis in late
      lesions. S&aacute;nchez at al.<sup><a href="#FN151"><font
      size="-1">151</font></a></sup> described the histologic
      curiosity of vulvar LS with loss of papillary dermis elastin
      coexisting with an underlying nevus elasticus, an elastic
      tissue hamartoma characterized by dense, mid-dermal elastic
      fibers.<br />
       &nbsp;&nbsp;&nbsp; A lichenoid mononuclear infiltrate may be
      dense and extensive or relatively sparse and patchy,
      especially in older lesions. Plasma cells have been
      reported;<sup><font size="-1"><a href="#FN88">88,</a><a
      href="#FN114">114</a></font></sup> others believe this is
      more likely in similar diseases such as acrodermatitis
      chronica atrophicans.<sup><a href="#FN157"><font
      size="-1">157</font></a></sup> Eosinophils are an unusual
      finding,<sup><font size="-1"><a href="#FN35">35,</a><a
      href="#FN158">158</a></font></sup> but, Janovski and
      Ames<sup><a href="#FN159"><font
      size="-1">159</font></a></sup> found significant tissue
      eosinophilia in 10% of their specimens. Mast cells may be
      increased,<sup><font size="-1"><a href="#FN74">74,</a> <a
      href="#FN95">95</a></font></sup> decreased,<sup><a
      href="#FN160"><font size="-1">160</font></a></sup> or
      unchanged.<sup><a href="#FN154"><font
      size="-1">154</font></a></sup> Additional findings in LS
      include a characteristic nerve degeneration and regeneration
      in the papillary dermis<sup><font size="-1"><a
      href="#FN141">141,</a><a href="#FN161">161</a></font></sup>
      and milia, thought to be of eccrine origin,<sup><font
      size="-1"><a href="#FN114">114,</a><a
      href="#FN162">162</a></font></sup> in 15% of routine
      histopathologic specimens. Hewitt<sup><a href="#FN138"><font
      size="-1">138</font></a></sup> describes a detailed
      histologic grading system for vulvar LS that could be applied
      in other studies of LS.<br />
      <br />
       

      <p><b><font face="Arial"><font size="+0">GENITAL LS AND THE
      RISK OF MALIGNANCY</font></font></b><br />
       &nbsp;&nbsp;&nbsp; The treatment of genital LS has been
      primarily surgical until recently. Issues concerning male
      genital LS (BXO) are relatively straightforward. Some
      initially suggested restricting the diagnosis BXO to those
      cases in which there was meatal stenosis (seen in up to 25%
      of patients).<sup><font size="-1"><a href="#FN87">87,</a> <a
      href="#FN163">163</a></font></sup> Meatal stenosis can occur
      without involvement of the remainder of the glans
      penis.<sup><font size="-1"><a href="#FN88">88,</a> <a
      href="#FN164">164</a></font></sup> The term <i>kraurosis
      penis</i> appears sporadically but never achieved widespread
      use.<sup><a href="#FN109"><font
      size="-1">109</font></a></sup>&nbsp; <span
      class="yellow">Reports of LS in circumcised men<sup><font
      size="-1"><a href="#FN52">52,</a><a href="#FN57">57,</a><a
      href="#FN165">165</a></font></sup>are conspicuous in a
      literature dominated by the concept that LS arises only in
      the incompletely or uncircumcised man<sup><font size="-1"><a
      href="#FN59">59,</a><a href="#FN110">110</a></font></sup>
      caused by irritation, chronic balanitis, or subclinical
      trauma.</span><br />
       &nbsp;&nbsp;&nbsp; An understanding of the relation between
      LS and the foreskin is confounded by the frequent failure to
      report indications and age at circumcision of patients with
      LS. When LS appears in circumcised men, a history of previous
      phimosis or adhesions is common. This many imply a
      preexisting LS condition because new onset or worsening
      phimosis and adhesion of the prepuce to the glans corona are
      key signs of male LS. LS, once considered rare in
      males,<sup><a href="#FN166"><font
      size="-1">166</font></a></sup> may be much more frequent than
      thought.<sup><font size="-1"><a href="#FN61">61,</a><a
      href="#FN114">114,</a><a href="#FN167">167</a></font></sup>
      Even in prepubertal boys, examination of foreskins submitted
      to histopathologic examination for various conditions
      (usually phimosis) reveals a significant percentage of LS
      (3.5% to 19%),<sup><font size="-1"><a href="#FN57">57,</a><a
      href="#FN60">60,61,</a><a href="#FN114">114,</a><a
      href="#FN168">168</a></font></sup> often unsuspected. <span
      class="yellow">Skewing the statistics further, many normal,
      nonretractile prepubertal foreskins are submitted under the
      diagnosis of "phimosis," a condition that is diagnosed far
      more often that it truly occurs.</span><sup><a
      href="#FN169"><font size="-1">169,170</font></a></sup> If
      only truly sclerosed and stenotic foreskins were considered
      under this diagnosis, the incidence of LS can be as high as
      95%.<sup><a href="#FN171"><font
      size="-1">171-173</font></a></sup><br />
       &nbsp;&nbsp; Despite an oft-quoted association of penile LS
      and cancer,<sup><a href="#FN59"><font
      size="-1">59</font></a></sup> we found only nine clearly
      defined cases.<sup><font size="-1"><a
      href="#FN112">112,</a><a
      href="#FN174">174-176</a></font></sup> At least two
      associated malignancies, Bowen's disease<sup><font
      size="-1"><a href="#FN48">48,</a><a
      href="#FN177">177</a></font></sup> and verrucous
      carcinoma,<sup><a href="#FN178"><font
      size="-1">178</font></a></sup> may have contributing factors
      such as human papillomavirus (HPV) infection. <span
      class="yellow">Penile malignancies are associated with
      phimosis-related hygiene problems, and it may be the phimosis
      itself rather than the LS that caused it that is the true
      risk factor.</span> Nevertheless, for penile LS circumcision
      is considered the treatment of choice for both therapeutic
      and prophylactic purposes. <span class="yellow">Medical
      therapies are generally reserved for those who have already
      been circumcised or those with persistent symptoms after
      surgery. After circumcision, it is not uncommon, especially
      in young adults, to have persistent plaques, discoloration,
      and occasional ulceration.</span><sup><font size="-1"><a
      href="#FN21">21,</a><a href="#FN89">89</a></font></sup><br />
       &nbsp;&nbsp;&nbsp; As in male genital LS, the prevalence of
      female genital LS is likely to be much higher than Wallace's
      oft-quoted 1 in 300 to 1 in 1000.<sup><a href="#FN21"><font
      size="-1">21</font></a></sup> Up to 12% of patients with
      idiopathic vulvadynia [sic] may have LS.<sup><a
      href="#FN179"><font size="-1">179</font></a></sup> Thorough
      autopsy studies and more liberal use of biopsy in patients
      with genital complaints could better define the prevalence of
      LS.<sup><a href="#FN180"><font
      size="-1">180</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Adding to the confusion, the gynecologic
      literature on LS is replete with biases and taxonomic
      disorder. Reports contain various definitions of "lichen
      sclerosus," "kraurosis vulvae," "gross atrophy," "simple
      atrophy," "senile atrophy," and "vaginal dystrophy." The term
      <i>leukoplakia</i> is particularly obscure. Leukoplakia has
      been referred to as a clinical observation that became a
      microscopic diagnosis and, ultimately, a prognostic
      imperative.<sup><a href="#FN102"><font
      size="-1">102</font></a></sup> Most cases of kraurosis
      vulvae, and "simple," "gross," and "senile" atrophy, as well
      as many conditions termed leukoplakia represent LS.<br />
       &nbsp;&nbsp;&nbsp; In 1976, the International Society for
      the Study of Vulvar Disease (SSDIV) [sic] classified LS as a
      vulvar dystrophy and devised a new classification system to
      address the ambiguities of nomenclature. When <i>hyperplastic
      dystrophy,</i> a term developed for this system, caused
      confusion on its own, a 1987 consensus modified the
      nomenclature once again (<a href="#Table3">Table III</a>). LS
      under both these systems is clinically and histologically
      identical to an identity long known to dermatologists as
      lichen sclerosus et atrophicus. The renaming and
      reclassification of LS was adopted by the gynecologic
      community, although it has been slow to find its way into the
      dermatologic and urologic literature.<sup><font size="-1"><a
      href="#FN16">16,</a><a href="#FN181">181,182</a></font></sup>
      On the adoption of the ISSVD's recommendations, several terms
      were deleted from use. These included lichen sclerosus et
      atrophicus, leukoplakia, neurodermatitis, leukokeratosis,
      leukoplakic vulvitis, hyperplastic vulvitis, and kraurosis
      vulvae. The terms Bowen's disease, erythroplasia of Queyrat,
      and carcinoma simplex were deleted in favor of the inclusive
      term squamous cell carcinoma in situ. Paget's disease of the
      vulva remains in a separate disease.</p>
      <hr noshade="noshade" width="90%" />
      <b><font face="Arial"><font size="+0">Table 3:<a id="Table3"
      name="Table3"></a> Nomenclature of vulvar
      disease</font></font></b><br />
       &nbsp; 

      <table summary="" border="0" width="80%">
        <tr>
          <td><b>1976 terminology*</b></td>

          <td><b>1987 terminology&dagger;</b></td>

          <td><b>Histologic description</b></td>
        </tr>

        <tr>
          <td>LS</td>

          <td>LS</td>

          <td>Hyperkeratosis, effacement of epidermis, variable
          interface vacuolization, homogenization and edema of
          papillary dermis, and lichenoid infiltrate</td>
        </tr>

        <tr>
          <td>Hyperplastic dystrophy without atypia</td>

          <td>Squamous cell hyperplasia</td>

          <td>Hyperkeratosis, acanthosis, epithelial hyperplasia
          without atypia and not attributable to a more specific
          dermatosis</td>
        </tr>

        <tr>
          <td>Mixed dystrophy without atypia</td>

          <td>(Report both conditions above)</td>

          <td>Features of LS and hyperplastic dystrophy without
          atypia</td>
        </tr>

        <tr>
          <td>(no equivalent)</td>

          <td>Other dermatoses</td>

          <td>Typical findings of a specific infectious or
          inflammatory disease (i.e., psoriasis, condyloma)</td>
        </tr>

        <tr>
          <td>Hyperplastic dystrophy with atypia</td>

          <td>VIN</td>

          <td>Degree of atypia or grade of VIN graded according to
          degree of squamous proliferation, nuclear atypia and
          pleomorphism, individual cell keratinization, mitotic
          activity above the basal layer, and disordered
          maturation</td>
        </tr>

        <tr>
          <td>Mixed dystrophy with atypia</td>

          <td>(Report both LS and VIN)</td>

          <td>Features of both LS and VIN</td>
        </tr>
      </table>

      <p><b><font size="-1"><i>VIN,</i> Vulvar intraepithelial
      neoplasia.</font></b><br />
       <b><font size="-1">* According to the "Vulvar dystrophy"
      classification of the 1976 ISSVD
      committee.</font></b><sup><font size="-2"><a
      href="#FN16">16,</a><a
      href="#FN182">182</a></font></sup><br />
       <b>&dagger; <font size="-1">According to the "Nonneoplastic
      epithelial disorders of skin and mucosa" and "Vulvar
      intraepithelial neoplasia" classification of the 1987 ISSVD
      committee.</font></b><sup><a href="#FN181"><font
      size="-2">181</font></a></sup><br />
      <br />
       &nbsp;&nbsp;&nbsp; The impetus behind standardization of
      terminology was an effort to determine the true malignant
      potential of vulvar LS. Wallace's malignancy rate was 4%,
      which he believed was artificially reduced by the number of
      his patients who had already undergone vulvectomy.<sup><a
      href="#FN21"><font size="-1">21</font></a></sup> The dominant
      figure in linking LS with cancer was Taussig. He wrote a
      series of articles between 1920 and 1940 in which vulvas,
      removed for malignancy, were examined and found also to have
      evidence of "leukoplakia" in 73% of specimens.<sup><font
      size="-1"><a href="#FN93">93,</a> <a
      href="#FN183">183-185</a></font></sup> Others proposed that
      LS represented an "advanced premalignant"<sup><a
      href="#FN186"><font size="-1">186</font></a></sup> condition
      with a "transformation" rate of 1% to 50% over the lifetime
      of the lesion.<sup><font size="-1"><a href="#FN87">87,</a> <a
      href="#FN147">147</a><a href="#FN21">,</a><a
      href="#FN180">180</a><a href="#FN21">,</a><a
      href="#FN187">187-193</a></font></sup> On the basis of these
      data, the treatment of choice for LS and other "white
      lesions" of the vulva was vulvectomy. After the observation
      that LS had a recurrence rate of up to 78% after
      surgery,<sup><font size="-1"><a href="#FN51">51,</a><a
      href="#FN159">159</a></font></sup> the recommendation was to
      try again,<sup><a href="#FN194"><font
      size="-1">194</font></a></sup> take wider surgical
      margins,<sup><a href="#FN195"><font
      size="-1">195</font></a></sup> or use frozen sections to
      ensure that all affected tissue was removed.<sup><a
      href="#FN187"><font size="-1">187</font></a></sup> In the
      literature of genital LS from 1920 through the mid 1970s, up
      to 30% of the patients enrolled in a study may have undergone
      vulvectomy for LS, leukoplakia, or even intractable pruritis.
      As late as 1987, descriptions of a technique for
      "prophylactic" total vulvectomy was described in the
      dermatologic literature.<sup><a href="#FN196"><font
      size="-1">196</font></a></sup> Vulvectomy is far from a
      benign procedure. Taussig<sup><a href="#FN185"><font
      size="-1">185</font></a></sup> reported an operative
      mortality rate of almost 10% that he attributed to the older
      age of his patients.<br />
       &nbsp;&nbsp;&nbsp; Investigators subsequently noticed that
      cancers were most likely to arise in areas of hyperplastic or
      mixed dystrophy rather than contiguously with areas of
      clear-cut LS.<sup><font size="-1"><a href="#FN51">51,</a><a
      href="#FN177">177</a></font></sup> In addition, an unknown
      number of patients with squamous cell carcinoma and LS in
      early reports received ionizing radiation as therapy. The
      contribution of radiation to future malignancy in the setting
      of LS is unknown.<sup><a href="#FN197"><font
      size="-1">197</font></a></sup> The prevailing thought is that
      although LS may be associated with other dystrophic changes
      with malignant potential, LS is not, itself, a premalignant
      condition and the association is more "casual than
      causal."<sup><font size="-1"><a href="#FN41">41,</a><a
      href="#FN47">47</a><a href="#FN21">,</a><a
      href="#FN140">140</a><a href="#FN21">,</a><a
      href="#FN198">198-199</a></font></sup> Furthermore, it was
      noted that conservative therapy could reverse the histologic
      changes of LS<sup><a href="#FN200"><font
      size="-1">200,201</font></a></sup> and hyperplastic
      dystrophy. It was suggested that a therapeutic trial of
      conservative therapy with biopsies of persistent erosions,
      erythoplakia, or unusual-looking areas was more reasonable
      than immediate "prophylactic" vulvectomy.<sup><font
      size="-1"><a href="#FN120">120,</a> <a
      href="#FN202">202</a></font></sup> Jeffcoate,<sup><a
      href="#FN119"><font size="-1">119</font></a></sup> in 1966,
      is usually credited with establishing the nonsurgical
      approach as appropriate for simple LS. However, sporadic
      reports of the "widely appreciated malignant potential of LS"
      appear to this day.<br />
       &nbsp;&nbsp;&nbsp; Recent studies support the concept that
      LS is not quiescently atrophic but is active metabolically.
      Studies measuring uptake of tritiated thymidine,<sup><font
      size="-1"><a href="#FN203">203</a>
      32</font></sup>P-radiolabeled phosphate,<sup><a
      href="#FN204"><font size="-1">204</font></a></sup> and
      acridine orange<sup><a href="#FN205"><font
      size="-1">205</font></a></sup> suggest LS is significantly
      more active than unaffected skin. Flow cytometry reveals some
      LS lesions to have aneuploidy commensurate with actinic
      keratoses and keratoacanthomas.<sup><a href="#FN206"><font
      size="-1">206</font></a></sup> However, there are problems
      with studies supporting a neoplastic potential of LS. These
      include failure to appreciate the normally increased
      metabolic activity in genital versus nongenital skin and the
      possibility that mononuclear cell infiltrates may lead to
      false-positive results based on techniques that assess
      nuclear activity.<sup><a href="#FN207"><font
      size="-1">207</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; A plausible explanation for the
      association of LS with cancer involves infection with
      HPV.<sup><a href="#FN208"><font
      size="-1">208,209</font></a></sup> It has been proposed that
      LS provides the "fertile field" on which an oncogenic virus
      may cause dysplastic changes.<sup><a href="#FN210"><font
      size="-1">210</font></a></sup> HPV is associated with
      hyperplastic dystrophy<sup><a href="#FN142"><font
      size="-1">142</font></a></sup> but is not consistently found
      in vulvar squamous cell carcinoma associated with LS.<sup><a
      href="#FN102"><font size="-1">102</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Many techniques have been suggested to
      detect more significant dystrophy and dysplasia in the
      examination of a patient with LS. Cytologic study by
      Papanicolau smears from the external genitalia was
      suggested<sup><a href="#FN200"><font
      size="-1">200</font></a></sup> but has been criticized as too
      insensitive.<sup><font size="-1"><a href="#FN208">208,</a><a
      href="#FN211">211</a></font></sup> Acetowhitening in
      conjunction with colposcopy<sup><font size="-1"><a
      href="#FN142">142,</a><a href="#FN212">212</a></font></sup>
      can be useful in finding areas of more hypertrophic
      dystrophy. Use of toluidine blue may increase the
      sensitivity.<sup><font size="-1"><a href="#FN92">92,</a><a
      href="#FN180">180</a><a href="#FN21">,</a><a
      href="#FN200">200,</a><a href="#FN208">208</a></font></sup>
      However, false-positive findings may occur when toluidine
      blue stains lymphocyte nuclei in the lichenoid infiltrate
      under a thinned epidermis and mimics a more dysplastic
      process.<sup><a href="#FN213"><font
      size="-1">213</font></a></sup> With or without adjunctive
      techniques any ulcerated, friable, thickened, red, and
      nodular areas should be subjected to biopsy. However, the
      potential sampling error inherent with punch biopsies should
      be kept in mind.<sup><font size="-1"><a
      href="#FN200">200,</a><a
      href="#FN212">212</a></font></sup><br />
       &nbsp;&nbsp;&nbsp; Although squamous cell carcinoma is the
      primary malignancy associated with LS, other tumors have been
      rarely reported. These include basal cell
      epithelioma<sup><font size="-1"><a href="#FN116">116,</a><a
      href="#FN214">214</a></font></sup> and melanoma.<sup><a
      href="#FN215"><font size="-1">215</font></a></sup> Despite a
      single report of several basal cell epitheliomas arising in
      extensive LS of the shoulders,<sup><a href="#FN216"><font
      size="-1">216</font></a></sup> it is generally accepted that
      cancer does not occur in extragenital or pediatric LS.<sup><a
      href="#FN217"><font size="-1">217</font></a></sup></p>

      <p><b><font face="Arial"><font size="+0">LS AND
      SCLERODERMA</font></font></b><br />
       &nbsp;&nbsp;&nbsp; In 1910 Ormsby cautioned not to confuse
      LS with scleroderma<sup><a href="#FN218"><font
      size="-1">218</font></a></sup> and set the stage for what
      would be decades of debate regarding their association. Many
      authors have described coexistent LS and morphea, at all ages
      and in both sexes.<sup><font size="-1"><a
      href="#FN134">134,</a> <a
      href="#FN219">219-225</a></font></sup> Morphea and LS
      coexisting in the same biospy specimen has likewise been
      described.<sup><font size="-1"><a href="#FN139">139,</a> <a
      href="#FN226">226,227</a></font></sup> Although most reports
      describe extragenital LS associated with morphea, there is
      mention of genital LS and extragenital morphea.<sup><font
      size="-1"><a href="#FN105">105,</a><a
      href="#FN228">228</a></font></sup> Wallace<sup><a
      href="#FN21"><font size="-1">21</font></a></sup> reported 13
      patients with morphea in his series of 380 patients. The
      frequency of the reported association leads many to assume a
      relation between the two.<sup><font size="-1"><a
      href="#FN72">72,</a><a href="#FN229">229,230</a></font></sup>
      With sequential biopsies, several investigators have reported
      transition from LS to morphea<sup><a href="#FN227"><font
      size="-1">227</font></a></sup> or vice versa.<sup><a
      href="#FN24"><font size="-1">24</font></a></sup> Borda et
      al.<sup><a href="#FN73"><font size="-1">73</font></a></sup>
      view LS as a scleroderma of the papillary dermis and classify
      LS as a subset of the greater body of scleroderma and
      "pseudo-scleroderma" diseases. They further resurrect the
      long-abandoned term "white spot scleroderma" as a
      transitional condition. Others view LS and morphea as
      manifestations of the same disease with morphea having a
      greater association with systemic disease.<sup><a
      href="#FN231"><font size="-1">231,232</font></a></sup> The
      proposal that LS, morphea, and systemic scleroderma are
      borrelial disease has received much recent attention.<sup><a
      href="#FN233"><font size="-1">233</font></a></sup>
      Acrodermatitis chronica atrophicans (ACA), well established
      as a spirochetal disease, is often considered the bridge
      between LS and morphea because of the degree of clinical and
      histologic overlap it shows.<sup><a href="#FN234"><font
      size="-1">234-237</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; However, many investigators believe there
      are enough clinical and histologic differences between LS and
      morphea to argue they are distinct if not unrelated
      diseases,&nbsp; and that coexistent lesions are
      coincidental.<sup><font size="-1"><a href="#FN45">45,</a> <a
      href="#FN148">148</a><a href="#FN116">,</a><a
      href="#FN150">150</a><a href="#FN116">,</a><a
      href="#FN238">238,239</a></font></sup> Morphea does not have
      the immunoreactant deposition at the dermoepidermal junction
      and papillary dermis that LS often does.<sup><a
      href="#FN240"><font size="-1">240</font></a></sup> Different
      lectin staining patterns have also been reported; only LS
      stains with <i>Eulex eropaeus.</i><sup><a href="#FN241"><font
      size="-1">241</font></a></sup> The loss of elastic fibers
      characteristic of LS is not found in morphea<sup><a
      href="#FN151"><font size="-1">151</font></a></sup>; beyond
      the differences in gross histologic features, changes in the
      dermal ground substance and dermoepidermal junction are
      distinct.<sup><a href="#FN145"><font
      size="-1">145</font></a></sup> Collagen biosynthesis is
      generally increased in scleroderma and decreased in
      LS.<sup><a href="#FN242"><font
      size="-1">242,243</font></a></sup> Transforming growth
      factor-<font face="Symbol">b</font> is increased in
      scleroderma and not in active LS.<sup><a href="#FN244"><font
      size="-1">244</font></a></sup> Morphea and ACA have similar
      nerve degeneration patterns that are distinct from LS.<sup><a
      href="#FN161"><font size="-1">161</font></a></sup> Patterson
      and Ackerman<sup><a href="#FN245"><font
      size="-1">245</font></a></sup> raised the issue that many
      cases diagnosed clinically and histologically as LS are
      actually morphea when sclerosus in the reticular dermis and
      subcutis are appreciated. They classify any case with
      involvement beyond the papillary dermis as morphea,
      regardless of how consistent the more superficial histologic
      characteristics may be with LS. They further suggest that the
      lack of significant infiltrate and minimal vacuolar interface
      changes in many cases in their series support a diagnosis of
      morphea. Earlier, however, Ackerman<sup><a
      href="#FN139"><font size="-1">139,140</font></a></sup> noted
      that late sclerotic lesions of LS may have only sparse
      infiltrate and interface changes.</p>

      <p><b><font face="Arial"><font size="+0">LS, HLA, AND
      AUTOIMMUNE ASSOCIATIONS</font></font></b><br />
       &nbsp;&nbsp;&nbsp; Beginning in 1910, with the report of a
      patient with both LS and diabetes mellitus,<sup><a
      href="#FN218"><font size="-1">218</font></a></sup> attempts
      have been made to link LS with known or suspected autoimmune
      disorders or with the presence of autoantibodies.<sup><a
      href="#FN246"><font size="-1">246,247</font></a></sup>
      Vitiligo and alopecia areata have been reported in
      association with genital and extragenital LS in both
      sexes.<sup><font size="-1"><a href="#FN19">19,</a><a
      href="#FN21">21,</a><a href="#FN43">43,</a><a
      href="#FN248">248-253</a></font></sup> Thyroid disease,
      especially Graves' disease,<sup><font size="-1"><a
      href="#FN63">63,</a><a href="#FN254">254,255</a></font></sup>
      and both type I and type II diabetes are likewise reported in
      LS.<sup><font size="-1"><a href="#FN48">48,</a><a
      href="#FN87">87,</a><a href="#FN105">105,</a><a
      href="#FN147">147,</a><a href="#FN224">224,</a><a
      href="#FN256">256</a></font></sup> Other conditions thought
      to be immune-mediated and associated with LS include lichen
      planus,<sup><font size="-1"><a href="#FN19">19,</a><a
      href="#FN222">222,</a><a href="#FN257">257</a></font></sup>
      eczema and atopic dermatitis,<sup><font size="-1"><a
      href="#FN106">106,</a><a href="#FN253">253</a></font></sup>
      polymyalgia rheumatica,<sup><a href="#FN252"><font
      size="-1">252</font></a></sup> psoriasis,<sup><a
      href="#FN251"><font size="-1">251</font></a></sup> primary
      biliary cirrhosis,<sup><font size="-1"><a
      href="#FN124">124,</a> <a
      href="#FN258">258,259</a></font></sup> fasciitis,<sup><font
      size="-1"><a href="#FN220">220,</a> <a
      href="#FN257">257</a></font></sup> myositis,<sup><font
      size="-1"><a href="#FN231">231,</a> <a
      href="#FN260">260</a></font></sup> lupus panniculitis,<sup><a
      href="#FN257"><font size="-1">257</font></a></sup> systemic
      lupus erythematosus,<sup><a href="#FN132"><font
      size="-1">132</font></a></sup> and achlorhydria, with or
      without pernicious anemia.<sup><font size="-1"><a
      href="#FN251">251,</a><a
      href="#FN261">261,262</a></font></sup><br />
       &nbsp;&nbsp;&nbsp; Various autoantibodies have been reported
      to be more common in patients with LS, including thyroid
      antimicrosomal, antigastric parietal cell, and antinuclear
      antibodies.<sup><font size="-1"><a href="#FN250">250,</a><a
      href="#FN255">255,</a><a href="#FN263">263</a></font></sup>
      Anti-adrenal cortex<sup><a href="#FN129"><font
      size="-1">129</font></a></sup> and
      anti-mitochondrial<sup><font size="-1"><a
      href="#FN259">259,</a><a href="#FN264">264</a></font></sup>
      antibodies are less commonly detected. A large study of 350
      female patients with LS revealed 21.5% with at least one
      autoimmune disease and 42% with at least one
      autoantibody.<sup><a href="#FN189"><font
      size="-1">189</font></a></sup> A comparable study of 25 men
      with LS revealed 20% with vitiligo or alopecia areata and 36%
      with autoantibodies (mostly antismooth muscle and antigastric
      parietal cell).<sup><font size="-1"><a href="#FN250">250,</a>
      <a href="#FN265">265,266</a></font></sup> Direct
      immunofluorescence has demonstrated nonspecific deposition of
      IgM, C3, and fibrin at the dermoepidermal junction and
      papillary dermis.<sup><a href="#FN267"><font
      size="-1">267,268</font></a></sup> Perivascular IgG and IgA
      were found in 63% of foreskins removed for LS.<sup><a
      href="#FN114"><font size="-1">114</font></a></sup> Elastic
      fibers with irregular diameters are seen in LS and are also
      characteristic of connective tissue disease.<sup><a
      href="#FN154"><font size="-1">154</font></a></sup> Carli et
      al.<sup><a href="#FN269"><font size="-1">269</font></a></sup>
      recently characterized the inflammatory infiltrate in LS and
      demonstrated consistently increased numbers of Langerhans
      cells, regardless of the age of the lesion and amount of
      infiltrate.<br />
       &nbsp;&nbsp;&nbsp; Even advocates of an association of
      autoantibodies and autoimmune diseases with LS note that
      disease severity may be unrelated to these factors<sup><a
      href="#FN250"><font size="-1">250</font></a></sup> and that
      autoimmune conditions often predate the appearance of LS.
      Therefore an exhaustive search for these diseases is not
      mandated in a patient with LS.<sup><a href="#FN270"><font
      size="-1">270,271</font></a></sup> Perhaps the most
      provocative association between LS and an autoimmune
      phenomenon is a description of "paraneoplastic LS" in the
      comments to a case report in 1973.<sup><a href="#FN272"><font
      size="-1">272</font></a></sup> Here Curth described patients
      with unspecified internal malignancies whose LS was
      alleviated with tumor resection and flared with tumor
      recurrence. This is analogous to paraneoplastic pemphigus and
      has not been reported since.<br />
       &nbsp;&nbsp;&nbsp; Finally, LS has been reported in
      identical<sup><font size="-1"><a href="#FN65">65,</a><a
      href="#FN273">273</a></font></sup> and nonidentical
      twins,<sup><a href="#FN274"><font
      size="-1">274</font></a></sup> a pair of young
      sisters,<sup><a href="#FN100"><font
      size="-1">100</font></a></sup> three adult sisters,<sup><a
      href="#FN248"><font size="-1">248</font></a></sup> mothers
      and daughters,<sup><font size="-1"><a href="#FN11">11,</a> <a
      href="#FN217">217</a></font></sup> and a brother and a
      sister.<sup><a href="#FN38"><font
      size="-1">38</font></a></sup> However, no consistent
      autosomal or X-linked genetic pattern has been determined and
      haplotype studies provide conflicting results.<sup><font
      size="-1"><a href="#FN44">44,</a><a
      href="#FN275">275</a></font></sup> HLA haplotypes reported to
      be associated with LS include HLA B-40,<sup><font
      size="-1"><a href="#FN217">217,</a><a
      href="#FN276">276</a></font></sup> Aw-30, Aw-31,<sup><a
      href="#FN277"><font size="-1">277</font></a></sup> DR-5,
      DR-7, B-21,<sup><a href="#FN278"><font
      size="-1">278</font></a></sup> A29, B-44,<sup><a
      href="#FN279"><font size="-1">279</font></a></sup> and
      B-27.<sup><a href="#FN280"><font
      size="-1">280</font></a></sup></p>

      <p><b><font face="Arial"><font size="+0">PATHOGENESIS OF
      LS</font></font></b><br />
       &nbsp;&nbsp;&nbsp; Most early reports of LS suggested the
      victims were primarily women who were "hysterical,"
      "excitable," or "highly nervous."<sup><font size="-1"><a
      href="#FN218">218,</a><a
      href="#FN281">281,282</a></font></sup> As late as 1952
      nervousness was reported as a risk factor for LS.<sup><a
      href="#FN120"><font size="-1">120</font></a></sup> In 1903
      Johnston and Sherwell<sup><a href="#FN74"><font
      size="-1">74</font></a></sup> proposed that local
      interference with blood supply led to LS and this idea was
      echoed in 1993.<sup><a href="#FN69"><font
      size="-1">69</font></a></sup> In 1913 Irvine<sup><a
      href="#FN237"><font size="-1">237</font></a></sup> injected
      serum from a patient with "dermatitis atrophicans maculosa"
      (which by its description may have been either LS or ACA)
      into healthy skin and produced an isolated atrophic plaque.
      Recent investigators have shown a subpopulation of dermal
      fibroblasts that proliferate on incubation with serum from
      patients with scleroderma.<sup><a href="#FN283"><font
      size="-1">283,284</font></a></sup> The factors causing
      inflammation and fibrosis in LS and scleroderma may be
      immunologically related in the same way idiopathic
      scleroderma and chronic graft-versus-host disease share
      common clinical and histologic features.<sup><a
      href="#FN226"><font size="-1">226</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; The concept that some, if not all, cases
      of LS might be caused by an infectious disease is not new.
      Beyond the possibility that a chronic "garden variety"
      infection might generate the isomorphic phenomenon<sup><font
      size="-1"><a href="#FN102">102,</a><a
      href="#FN122">122</a></font></sup> attempts to isolate the
      responsible organism have yielded conflicting results.
      Cantwell<sup><a href="#FN285"><font
      size="-1">285,286</font></a></sup> proposed that an L-form,
      or cell-wall-deficient, atypical mycobacterium such as
      <i>Mycobacterium, fortuitum</i> caused scleroderma and LS.
      "Large bodies," invariably acid fast with the Fite strain,
      were identified around deep dermal blood vessels, eccrine
      glands, nerves, and in the fat. These bodies were sometimes
      difficult to distinguish from lipofuchsin, melanin, and
      hemosiderin deposits, and there are no recent follow-up
      reports. T&ouml;r&ouml;k et al.,<sup><a href="#FN95"><font
      size="-1">95</font></a></sup> in a electronmicroscopic study
      of LS in children published in 1975, noted tubular particles
      in endothelial cells and fibrocytes that resembled
      paramyxovirus-like inclusion bodies. Despite the conclusion
      that these were probably not of viral origin and instead
      represented aberrant cytoplasmic tubules, the idea of a slow
      virus generating an autoimmune reponse was advanced. Others
      have also proposed an unspecified viral cause for LS.<sup><a
      href="#FN172"><font size="-1">172</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; In a 1913 case report of LS, the comment
      was made that the concern in properly classifying this new
      entity was unfounded because it was just another
      manifestation of syphilis.<sup><a href="#FN281"><font
      size="-1">281</font></a></sup> Although syphilis has been
      reported in patients with LS,<sup><font size="-1"><a
      href="#FN18">18,</a><a href="#FN287">287</a></font></sup> a
      new spirochete is the center of interest. In addition to the
      research on the relation of <i>Borrelia burgdorferi</i> to
      scleroderma are many reports linking LS to this spirochete.
      ACA, once thought a form of scleroderma, and at times
      coexistent with LS,<sup><font size="-1"><a
      href="#FN157">157,</a><a href="#FN256">256</a></font></sup>
      is now well established as a borrelial disease.<sup><font
      size="-1"><a href="#FN234">234,</a><a
      href="#FN288">288</a></font></sup> Researchers have found
      spirochetes in the papillary dermis of as many as 48% of
      patients with LS, especially in early cases.<sup><a
      href="#FN289"><font size="-1">289</font></a></sup> Six of 13
      patients with predominantly genital LS has spirochetes
      revealed by immunoperoxidase methods, inclduing a possible
      organism in a focus of basilar degeneration.<sup><a
      href="#FN290"><font size="-1">290</font></a></sup> Two
      patients with neuroborreliosis had both localized and
      generalized LS.<sup><a href="#FN233"><font
      size="-1">233</font></a></sup> Another patient with ACA and
      genital LS had spirochetes recovered from his urine.<sup><a
      href="#FN256"><font size="-1">256</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Tuffanelli<sup><a href="#FN291"><font
      size="-1">291</font></a></sup> noted that false-positive
      borrelial immunofluorescence tests may occur because of
      coexistent connective tissue diseases and other spirochetal
      infections. Recognizing the problems with identifying
      spirochetes on special stains, a recent study employed the
      lymphocyte proliferative assay, a method of detecting prior
      T-cell sensitization to a specific antigen, and found their
      two patients with LS had both elevated borrelial antibodies
      and high lymphoproliferative responses.<sup><a
      href="#FN232"><font size="-1">232</font></a></sup> Acceptance
      of a borrelial cause for LS is far from universal and there
      are several negative studies.<sup><font size="-1"><a
      href="#FN150">150,</a><a href="#FN242">242</a></font></sup>
      It would be difficult to explain all LS, especially the
      number of genital cases and those in very young children, on
      the basis of arthropod vector. Better modles for a
      spirochetal cause of LS might be those of endemic syphilis
      (bejel) or pinta. These spirochetal diseases are spread
      nonvenereally and affect even young children. In the case of
      pinta, the disease is confined to the skin.<sup><a
      href="#FN292"><font size="-1">292</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Independent of autoantibodies, a possible
      mechanism of spirochete-induced fibrosis was revealed by the
      observation that killed spirochetes induced a macrophage
      culture to produce interleukin 1 (IL-1).<sup><a
      href="#FN293"><font size="-1">293</font></a></sup>
      Fibroblasts, under the influence of IL-1, proliferate and
      increase secretion of collagenase and prostaglandin
      E<sub><font size="-1">2</font></sub>. The continued
      production of IL-1 and other cytokines by
      <i>Borrelia-</i>activated T cells could maintain fibroblast
      stimulation resulting in the fibrosis in scleroderma and late
      LS.<sup><a href="#FN232"><font size="-1">232</font></a></sup>
      It is thought this effect of spirochetal antigens explains
      the occurrence of disease without identifiable spirochetes.
      Spirochetes are not the only source of fibrosis-stimulating
      antigens. A cellular immune reponse to collagen itself was
      suggested by one scleroderma study,<sup><a
      href="#FN294"><font size="-1">294</font></a></sup> and a
      collagen-induced migration inhibition factor has been studied
      in fibrotic lung disease.<sup><a href="#FN295"><font
      size="-1">295</font></a></sup> Pneumococcal polysaccharides
      in the presence of serum can also induce DNA synthesis in
      fibroblasts in the absence of macrophages.<sup><a
      href="#FN296"><font size="-1">296</font></a></sup> In
      scleroderma, fibroblasts were found to secrete procollagen
      types I and III in a normal ratio but at a rate twice that of
      control cells.<sup><a href="#FN297"><font
      size="-1">297</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Although collagen changes in LS are often
      analagous to the changes in scleroderma, they exhibit some
      important differences. Some report decresed collagen
      synthesis, both type I and type III, in LS.<sup><font
      size="-1"><a href="#FN138">138,</a><a href="#FN242">242</a><a
      href="#FN102">,</a><a href="#FN298">298</a></font></sup>
      Others report a slight increase in the synthesis of a
      younger, more soluble type I collagen<sup><a
      href="#FN244"><font size="-1">244</font></a></sup> or
      evidence of increased turnover and intracellular degradation
      without a significant net gain or loss.<sup><a
      href="#FN298"><font size="-1">298</font></a></sup> Still
      others have detected increased ground substance and evidence
      of collagen degeneration and regeneration with fewer normal
      fibers.<sup><a href="#FN146"><font
      size="-1">146</font></a></sup> Increased activity of amidase,
      an elastase-type protease, which is able to degrade human
      skin elastin, may cause the elastic tissue destruction in
      LS.<sup><font size="-1"><a href="#FN146">146,</a> <a
      href="#FN299">299</a></font></sup> Retinoids down-regulate
      fibroblast proliferation and synthesis, which explains the
      utility of reinoids in treating LS.<sup><a
      href="#FN300"><font size="-1">300</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Suggested by frequent local recurrence
      after vulvectomy, the contribution of local factors to the
      development and presistence of LS is well recognized. Some
      attribute this to continued factors of friction from opposed
      skin surfaces,<sup><font size="-1"><a
      href="#FN125">125,</a><a href="#FN137">137</a></font></sup>
      chronic infection,<sup><font size="-1"><a
      href="#FN117">117,</a><a href="#FN119">119</a></font></sup>
      irritation from glycosuria or other sources of chronic
      irritation.<sup><a href="#FN119"><font
      size="-1">119</font></a></sup> However, such factors do not
      apply to all cases of genital LS and few cases of
      extragenital LS. More provocative regarding the relevance of
      local factors are reports of recurrent LS of the scalp
      several years after excision and grafting,<sup><a
      href="#FN63"><font size="-1">63</font></a></sup> vulvar LS
      reappearing in a myocutaneous graft from the thigh,<sup><a
      href="#FN116"><font size="-1">116</font></a></sup> and an
      oft-quoted observation by Whimster,<sup><a
      href="#FN115"><font size="-1">115</font></a></sup> who
      reported that normal skin grafted to an involved vulva
      developed LS, whereas a graft of LS-involved skin applied to
      the donor site became normal in texture and appearance.<br />
       &nbsp;&nbsp;&nbsp; The interaction of hormones, fibroblasts,
      local changes in collagen, cytokines, and other growth
      factors have been studied for several decades without
      universal agreement on the pathogenesis of LS. Hormonal
      studies in LS center on the actions of testosterone.
      Androgen-sensitive fibroblasts in genital skin facilitate
      collagen and glycosaminoglycan production.<sup><a
      href="#FN301"><font size="-1">301,302</font></a></sup> The
      increased testosterone metabolism in genital skin, which
      occurs at menarche, is believed to cause the spontaneous
      improvement that often occurs in childhood vulvar LS.<sup><a
      href="#FN303"><font size="-1">303</font></a></sup> In fact,
      adults with LS were found to have decreased serum levels of
      free testosterone, androstenedione, and fihydrotestosterone
      compared with control subjects. A defect in the function of
      5<font face="Symbol">a</font>-reductase, an enzyme usually
      showing increased activity in genital skin compared with
      nongenital skin,<sup><font size="-1"><a
      href="#FN302">302,</a> <a
      href="#FN304">304,305</a></font></sup> is believed to be the
      underlying defect predisposing these patients to LS.<sup><a
      href="#FN303"><font size="-1">303</font></a></sup> A study of
      risk factors for LS revealed that nonsmokers were
      significantly more likely to have LS than smokers. The
      authors conjecture that this is caused by the
      androgen-elevating effect of cigarette smoking.<sup><a
      href="#FN306"><font size="-1">306</font></a></sup></p>

      <p><b><font face="Arial"><font
      size="+0">TREATMENT</font></font></b><br />
       &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS was initially
      treated with a variety of irritating and keratolytic agents
      knowns as "revulsives." This resulted in inflammation and
      tissue damage with anticipated clinical improvement. Such
      agents include salicylic acid, trichloroacetic acid,
      resorcin,<sup><font size="-1"><a href="#FN65">65,</a> <a
      href="#FN67">67</a><a href="#FN302">,</a><a
      href="#FN74">74,</a><a href="#FN281">281,</a><a
      href="#FN287">287,</a><a href="#FN307">307</a></font></sup>
      thymol,<sup><font size="-1"><a href="#FN50">50,</a><a
      href="#FN84">84,</a><a href="#FN308">308</a></font></sup>
      boric acid ointment,<sup><a href="#FN309"><font
      size="-1">309</font></a></sup> carbolic acid,<sup><a
      href="#FN93"><font size="-1">93</font></a></sup> and carbol
      fuchsin.<sup><a href="#FN94"><font
      size="-1">94</font></a></sup> Physically destructive methods
      include suction cups,<sup><a href="#FN281"><font
      size="-1">281</font></a></sup> cryotherapy,<sup><font
      size="-1"><a href="#FN21">21,</a> <a href="#FN94">94</a><a
      href="#FN302">,</a><a href="#FN197">197,</a><a
      href="#FN208">208</a></font></sup> fulguration and
      desiccation,<sup><font size="-1"><a href="#FN94">94,</a><a
      href="#FN208">208</a><a href="#FN302">,</a><a
      href="#FN310">310</a></font></sup> and tangential
      excision<sup><a href="#FN81"><font
      size="-1">81</font></a></sup> or dermabrasion.<sup><a
      href="#FN18"><font size="-1">18</font></a></sup> <span
      class="yellow">Carbon dioxide laser is the "modern
      revulsive." Used now primarily for treatment of hyperplastic
      vulvar dystrophies,<sup><font size="-1"><a
      href="#FN208">208,</a><a href="#FN210">210</a><a
      href="#FN302">,</a><a href="#FN212">212</a></font></sup> it
      has been applied to both vulvar<sup><font size="-1"><a
      href="#FN102">102,</a><a href="#FN311">311</a></font></sup>
      and penile LS<sup><a href="#FN312"><font
      size="-1">312,313</font></a></sup> with some
      benefit.</span><br />
       &nbsp;&nbsp;&nbsp; In the first half of the century genital
      and extragenital LS was treated with various forms of
      radiation from ultrasound<sup><a href="#FN260"><font
      size="-1">260</font></a></sup> to infrared<sup><a
      href="#FN84"><font size="-1">84</font></a></sup> to Grenz
      rays.<sup><a href="#FN50"><font size="-1">50</font></a></sup>
      More aggressive radiotherapy with topically applied thorium
      X<sup><font size="-1"><a href="#FN94">94,</a><a
      href="#FN122">122</a></font></sup> or "hard" x-rays<sup><font
      size="-1"><a href="#FN41">41,</a><a href="#FN53">53,</a><a
      href="#FN80">80,</a><a href="#FN93">93,</a><a
      href="#FN185">185,</a><a href="#FN218">218,</a><a
      href="#FN314">314,315</a></font></sup> persisted into the
      1940s, even in children. Eventually, various authors pointed
      out how temporary<sup><font size="-1"><a
      href="#FN117">117,</a><a href="#FN184">184</a></font></sup>
      the benefits were and how "evil radiation therapy"<sup><a
      href="#FN188"><font size="-1">188</font></a></sup> added
      clinical and histologic confusion as well as cancer risk to
      an otherwise benign process. The contribution of radiation
      therapy to the incidence of squamous cell carcinoma reported
      with LS in the earlier literature is uncertain. It is notable
      that most studies of the era report large numbers of patients
      so treated before the diagnosis of squamous cell
      carcinoma.<sup><a href="#FN183"><font
      size="-1">183-185</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Bismuth (topically,<sup><a
      href="#FN47"><font size="-1">47</font></a></sup>
      orally,<sup><font size="-1"><a href="#FN47">47,</a> <a
      href="#FN84">84</a></font></sup> and parenterally<sup><font
      size="-1"><a href="#FN308">308,</a> <a
      href="#FN316">316,317</a></font></sup>) was extensively used
      into the 1960s. Parenteral and oral mercury was likewise
      popular at one time.<sup><font size="-1"><a
      href="#FN49">49,</a> <a href="#FN247">247,</a><a
      href="#FN281">281,</a><a href="#FN307">307</a></font></sup>
      An unusual, relatively recent use of mercury involved
      tattooing the vulva with mercuric sulfide for intractable
      vulvar pruritis.<sup><a href="#FN318"><font
      size="-1">318</font></a></sup> Intravenous procaine<sup><font
      size="-1"><a href="#FN94">94,</a> <a
      href="#FN319">319</a></font></sup> and topical cocaine<sup><a
      href="#FN93"><font size="-1">93</font></a></sup> have also
      been used for persistent pruritis. However, allergic
      sensitization to topical anesthetics has been
      reported.<sup><a href="#FN94"><font
      size="-1">94</font></a></sup> Injection of alcohol into LS
      lesions<sup><a href="#FN320"><font
      size="-1">320-322</font></a></sup> or systemically in a
      gridlike fashion<sup><a href="#FN92"><font
      size="-1">92</font></a></sup> is still mentioned for relief
      of pruritis in recent texts on vulvar diseases.
      Antimalarials, orally<sup><font size="-1"><a
      href="#FN47">47,</a> <a href="#FN228">228,</a><a
      href="#FN231">231,</a><a href="#FN257">257,</a><a
      href="#FN323">323,324</a></font></sup> and
      intralesionally,<sup><a href="#FN325"><font
      size="-1">325</font></a></sup> have been reported beneficial
      in both penile and vulvar LS and have been employed in all
      age groups. Intralesional hyaluronidase was reported to be of
      no benefit.<sup><a href="#FN18"><font
      size="-1">18</font></a></sup> Potassium
      <i>para-</i>aminobenzoate (4 to 24 gm/day)<sup><a
      href="#FN326"><font size="-1">326</font></a></sup> is
      reported to be effective, possibly by decreasing
      mucopolysaccharide production.<sup><a href="#FN82"><font
      size="-1">82</font></a></sup> However, one study suggested it
      is not effective in men before circumcision.<sup><a
      href="#FN48"><font size="-1">48</font></a></sup> Chelation
      therapy<sup><font size="-1"><a href="#FN231">231,</a> <a
      href="#FN260">260</a></font></sup> and topical crotamiton
      (often in conjunction wiht a topical steroid)<sup><font
      size="-1"><a href="#FN179">179,180,</a><a
      href="#FN327">327</a></font></sup> have been used in hopes of
      remission or relief of associated pruritis. Topical<sup><a
      href="#FN80"><font size="-1">80</font></a></sup> and systemic
      antihistamines,<sup><font size="-1"><a
      href="#FN190">190,</a><a href="#FN231">231</a></font></sup>
      cool milk compresses, and application of vegetable shortening
      are also recommended for the pruritis of LS.<sup><a
      href="#FN328"><font size="-1">328</font></a></sup> One of the
      more dramatic surgical options for persistent vulvar
      pruritis, short of vulvectomy, is the "Mering procedure" that
      entails cutting the entire labial and pubic region to
      denervate the vulva.<sup><a href="#FN329"><font
      size="-1">329,330</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Surgery might still be the primary
      therapy for LS were it not for the introduction of hormonal
      therapy with corpus luteal extract injections in 1922.<sup><a
      href="#FN93"><font size="-1">93</font></a></sup> Parenteral
      adrenocorticotropic hormone (ACTH)<sup><font size="-1"><a
      href="#FN81">81,</a><a href="#FN83">83</a></font></sup> is a
      relatively recent innovation, whereas topical,<sup><font
      size="-1"><a href="#FN217">217,</a><a
      href="#FN248">248,</a><a href="#FN309">309</a></font></sup>
      intraurethral<sup><a href="#FN331"><font
      size="-1">331</font></a></sup> or intralesional<sup><font
      size="-1"><a href="#FN88">88,</a> <a href="#FN111">111,</a><a
      href="#FN165">165,</a><a href="#FN325">325,</a><a
      href="#FN332">332</a></font></sup> hydrocortisone or
      triamcinolone<sup><font size="-1"><a href="#FN21">21,</a><a
      href="#FN323">323</a><a href="#FN302">,</a><a
      href="#FN333">333-335</a></font></sup> have been the
      mainstays of genital<sup><a href="#FN102"><font
      size="-1">102</font></a></sup> and extragenital LS
      therapy.<sup><font size="-1"><a href="#FN260">260,</a><a
      href="#FN316">316</a></font></sup> Oral corticosteroids are
      likewise effective but generally reserved for patients with
      other indications for their use.<sup><a href="#FN222"><font
      size="-1">222</font></a></sup> Combining topical steroids
      with other modalities such as keratolytics,<sup><a
      href="#FN67"><font size="-1">67</font></a></sup>
      pramoxine,<sup><font size="-1"><a href="#FN180">180,</a> <a
      href="#FN328">328</a></font></sup> or occlusive
      therapy<sup><a href="#FN323"><font
      size="-1">323</font></a></sup> has additional benefits. <span
      class="yellow">Marked benefit has been reported from brief
      courses (usually 2 weeks or less) of topical fluorinated
      steroids<sup><font size="-1"><a href="#FN102">102,</a><a
      href="#FN254">254,</a><a href="#FN327">327,</a><a
      href="#FN335">335</a></font></sup> or clobetasol.<sup><a
      href="#FN54"><font size="-1">54</font></a></sup> Such
      regimens are used even in children,<sup><font size="-1"><a
      href="#FN56">56,</a><a href="#FN96">96,</a><a
      href="#FN101">101,</a><a href="#FN103">103</a></font></sup>
      and histologic regression of LS<sup><a href="#FN54"><font
      size="-1">54</font></a></sup> may occur as well as remarkable
      relief of symptoms.</span> A new approach to the nonsurgical
      treatment of phimosis is J&oslash;rgenssen and Swenson's 1993
      report<sup><a href="#FN173"><font
      size="-1">173</font></a></sup> in which clobetasol and gentle
      retraction were employed daily for up to 3 months and
      obviated the need for surgery in 70% of their patients. In
      this noncontrolled study, all patients failing to respond to
      topical therapy who underwent histologic examination of the
      foreskin were found to have LS.<br />
       &nbsp;&nbsp;&nbsp; Topical estrogen has benefitted both
      vulvar<sup><font size="-1"><a href="#FN80">80,</a><a
      href="#FN160">160,</a><a href="#FN316">316</a></font></sup>
      and penile<sup><a href="#FN77"><font
      size="-1">77</font></a></sup> LS, although some believe the
      results leave much to be desired. Intralesional estrogen was
      used in a case of penile LS<sup><a href="#FN336"><font
      size="-1">336</font></a></sup> as were oral conjugated
      estrogens<sup><a href="#FN260"><font
      size="-1">260</font></a></sup>; both provided some
      symptomatic relief. Topically applied testosterone, 2% to
      2.5%<sup><font size="-1"><a href="#FN87">87,</a> <a
      href="#FN74">74,</a><a href="#FN337">337</a></font></sup> in
      petrolatum or paraffin,<sup><a href="#FN102"><font
      size="-1">102</font></a></sup> has not only demonstrated
      clinical efficacy but also histologic regression,<sup><font
      size="-1"><a href="#FN254">254,</a><a
      href="#FN338">338-340</a></font></sup>although Cinberg<sup><a
      href="#FN341"><font size="-1">341</font></a></sup> in his
      description of the first documented use of topical
      testosterone found minimal histologic regression despite
      significant clinical improvement. Reversal of abnormal
      touidine blue uptake was noted in one study.<sup><a
      href="#FN160"><font size="-1">160</font></a></sup> Reported
      side effects include enlargement of the clitoris (5% to
      50%),<sup><a href="#FN342"><font
      size="-1">342</font></a></sup> increased libido (up to 50%),
      acne, virilization, and menstrual irregularities.<sup><font
      size="-1"><a href="#FN92">92,</a><a
      href="#FN254">254</a></font></sup> Increased serum levels of
      testosterone were not detected.<sup><a href="#FN253"><font
      size="-1">253</font></a></sup> Alternating testosterone with
      a topical corticosteroid is another strategy to minimize the
      side effects of either agent.<sup><a href="#FN92"><font
      size="-1">92</font></a></sup> Local irritation is common and
      may be minimized by reduction of the concentration of
      testosterone to as low as 0.5%<sup><font size="-1"><a
      href="#FN143">143,</a><a href="#FN343">343</a></font></sup>
      or compounding with a cream base instead of an
      ointment.<sup><a href="#FN329"><font
      size="-1">329</font></a></sup> Another means of avoiding the
      androgenic effects of testosterone, especially desirable in
      children, is the use of topical progesterone (200 mg in 2
      ounces of hydrophilic ointment).<sup><font size="-1"><a
      href="#FN254">254,</a><a
      href="#FN344">344,345</a></font></sup> However, progesterone
      is generally not as effective in hyperplastic dystrophy and
      slower to relieve symptomatic LS than testosterone.<sup><font
      size="-1"><a href="#FN117">117,</a><a
      href="#FN121">121</a></font></sup> Enhanced efficacy can be
      achieved by applying the progesterone in the morning and a
      topical corticosteroid, such as betamethasone ointment, at
      night.<sup><a href="#FN345"><font
      size="-1">345</font></a></sup><br />
       &nbsp;&nbsp;&nbsp; Nutritional therapy has been used in the
      treatment of LS. Oral administration of dilute hydrochloric
      acid was recommended because of the association with
      achlorhydria.<sup><a href="#FN195"><font
      size="-1">195</font></a></sup> Protein supplements,
      chlorophyll,<sup><a href="#FN190"><font
      size="-1">190</font></a></sup> and wheat germ oil<sup><font
      size="-1"><a href="#FN94">94,</a> <a href="#FN122">122,</a><a
      href="#FN346">346</a></font></sup> were staples in early
      nutritional therapies. Various B vitamins, orally and
      parenterally, have been recommended including B<sub><font
      size="-1">1</font></sub>,<sup><font size="-1"><a
      href="#FN308">308,</a><a href="#FN347">347</a></font></sup>
      B<sub><font size="-1">12</font></sub>,<sup><font size="-1"><a
      href="#FN94">94,</a><a href="#FN122">122</a></font></sup> and
      "B complex."<sup><a href="#FN347"><font
      size="-1">347</font></a></sup> Vitamin E has been recommended
      as adjunctive therapy<sup><a href="#FN217"><font
      size="-1">217</font></a></sup> (orally, topically, and
      intramuscularly), although it was not believed to be
      especially effective.<sup><font size="-1"><a
      href="#FN47">47,</a> <a href="#FN348">348</a></font></sup>
      Vitamin D has likewise been endorsed.<sup><a
      href="#FN80"><font size="-1">80</font></a></sup> Use of
      topical vitamin D analogues such as calcipotriene is not
      reported. One recommended concoctopn contained "vitamin
      F."<sup><a href="#FN58"><font size="-1">58</font></a></sup>
      Oral and parenteral vitamin A has been proposed; the ealier
      reports recommend nutritional supplements such as cod liver
      oil.<sup><font size="-1"><a href="#FN47">47,</a><a
      href="#FN83">83,</a><a href="#FN195">195,</a><a
      href="#FN308">308,</a><a href="#FN316">316,</a><a
      href="#FN349">349-351</a></font></sup> This is based on
      likening the hyperkeratosis seen in LS to a vitamin A
      deficiency and noting that achlorhydria, reported ofetn in
      LS, impairs absorption of vitamin A.<sup><a
      href="#FN351"><font size="-1">351</font></a></sup>
      Intralesional vitamin A was advocated by one group.<sup><a
      href="#FN353"><font size="-1">353</font></a></sup> Although
      no recent literature strongly advocates nutritional therapy
      for LS, the echoes of vitamin A therapy continue in current
      research on the efficacy of retinoids. Etretinate has been
      employed in dosages of 0.37 mg.kg per day<sup><a
      href="#FN343"><font size="-1">343</font></a></sup> to 1 mg/kg
      per day<sup><a href="#FN354"><font
      size="-1">354</font></a></sup> with measurable succcess even
      in patients who had recurrent disease after
      vulvectomy.<sup><a href="#FN355"><font
      size="-1">355</font></a></sup> Severely dysplastic and
      hyperkeratotic lesions are most likely to recur after
      therapy.<sup><a href="#FN343"><font
      size="-1">343</font></a></sup> Some report concomitant
      histologic improvement,<sup><font size="-1"><a
      href="#FN51">51,</a><a href="#FN355">355</a></font></sup>
      whereas others have noted only a decrease in
      hyperkeratosis.<sup><a href="#FN356"><font
      size="-1">356,357</font></a></sup> More recently acitretin
      (30 mg daily) has been used, and although pruritis was
      relieved, a large placebo response in this study made its
      ultimate efficacy less defined.<sup><a href="#FN25"><font
      size="-1">25</font></a></sup> Of note, the subjective and
      objective grading scale used in this report may have
      applications in future studies.<br />
       &nbsp;&nbsp;&nbsp; Careful attention to hygiene is
      recommended, and efforts to treat coexistent vaginal
      infections<sup><font size="-1"><a href="#FN102">102,</a><a
      href="#FN321">321</a></font></sup> or balanitis are
      essential. Because of the possible role of spirochetes in
      some cases of LS and morphea, many recommend empirical
      treatment with antispirochetal antibiotics such as penicillin
      or doxycycline.<sup><font size="-1"><a
      href="#FN184">184,</a><a href="#FN232">232,233,</a><a
      href="#FN291">291</a></font></sup> The utility of this
      therapy in LS remains to be defined.</p>

      <p><b><font face="Arial"><font size="+0">CONCLUSIONS AND
      UNANSWERED QUESTIONS</font></font></b><br />
       &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The true
      incidence of LS is unknown. Significant underreporting is
      likely for many reasons. These include faliure to recognize
      the condition, misdiagnosis as a related or unrelated
      disease, frequently asymptomatic patients, and reluctance to
      seek care because of embarassment or fear of legal
      complications (pediatric cases). Accurate epidemiology of LS
      is further hampered by fragmentation of case in various
      specialties (dermatology, gynecology, urology, pediatrics,
      family practice), many using different terminology for the
      same entity.<br />
       &nbsp;&nbsp;&nbsp; LS is an inflammatory condition caused by
      an incompletely defined response to a variety of mechanical
      and antigenic stimulu. These stimuli include, among others,
      trauma, spirochetal infection, and autoimmune diseases.<br />
       &nbsp;&nbsp;&nbsp; Further definition of the role of
      spirochetal diseases in LS is pivotal in making treatment
      recommendations. If this is a major cause of LS, the mode of
      transmission should be elucidated. Is the transmission via an
      insect vector (Lyme disease), sexually (venereal syphilis),
      or through casual person-to-person contact (endemic syphilis
      and pinta)?<br />
       &nbsp;&nbsp;&nbsp; LS and scleroderma, although clinically
      and histologically distinct entities that may coexist, share
      many pathogenic mechanisms. Perhaps they represent
      expressions of the same antigenic insult with LS being
      expressed in the papillary dermis and scleroderma in the
      reticular dermis and deeper. Differences in vascular adhesion
      molecuels, elastic network, and relative amounts of type I
      and III collagen may explain the differences between the two
      conditions. An unidentified genetic or environmental factor
      may determine which disease the patient acquires.<br />
       &nbsp;&nbsp;&nbsp; <span class="yellow">True LS is not
      itself a premalignant condition, although other white lesions
      that stimulate it, such as hyperplastic dystrophy, may be. LS
      should not be treated with aggressive surgical
      modalities.</span> Prior radiation therapy may have
      artificially increased historical rates of "malignant
      transformation." The contribution of human papillomavirus to
      current sporadic cases of LS-associated genital squamous cell
      carcinoma is unknown.<br />
       &nbsp;&nbsp;&nbsp; <span class="yellow">Urologists, in
      contrast to gynecologists, continue to view LS as primarily a
      surgical problem. Circumcision is still the most widely used
      primary therapy for genital LS in uncircumcised men. Reports
      of medical therapy are anecdotal and generally limited to
      persistent or recurrent lesions in patients already
      circumcised.</span><br />
       &nbsp;&nbsp;&nbsp; Medical therapies include retinoids and
      topical corticosteroids (including superpotent agents),
      testosterone, and progesterone. Other systemic and topical
      treatments have been used with variable success. Genital LS
      in children presents some special treatment concerns.</p>

      <p><b><font face="Arial"><font
      size="+0">REFERENCES:</font></font></b></p>

      <ol>
        <li><a id="FN1" name="FN1"></a><font face="Arial"><font
        size="-1"><b>Hallopeau H.</b> Le&ccedil;ons cliniques sur
        les malad&eacute;es cutan&eacute;es et syphiliques. Union
        Med Can 1887; 43: 472.</font></font></li>

        <li><a id="FN2" name="FN2"></a><font face="Arial"><font
        size="-1"><b>Weir RF.</b> Icthyosis of the tongue and
        vulva. NY State J Med 1875; 246.</font></font></li>

        <li><a id="FN3" name="FN3"></a><font face="Arial"><font
        size="-1"><b>Hallopeau H.</b> Lichen plan scl&eacute;reux.
        Ann Derm Syph (2nd series) 1889; 20:
        447-9.</font></font></li>

        <li><a id="FN4" name="FN4"></a><font face="Arial"><font
        size="-1"><b>Hallopeau H.</b> Sur un nouveau cas de lichen
        plan atrophique. Ann Derm Syph (3rd series)1896; 27:
        57-60.</font></font></li>

        <li><a id="FN5" name="FN5"></a><font face="Arial"><font
        size="-1"><b>Hallopeau H.</b> Sur un nouveau cas de lichen
        de Wilson scl&eacute;reux. Ann Derm Syph (3rd series) 1898;
        9: 358-9.</font></font></li>

        <li><a id="FN6" name="FN6"></a><font face="Arial"><font
        size="-1"><b>Darier J.</b> Le&ccedil;ons cliniques sur les
        malad&eacute;es cutan&eacute;es et syphiliques [Comment].
        Union Med Can 1887; 43: 472.</font></font></li>

        <li><a id="FN7" name="FN7"></a><font face="Arial"><font
        size="-1"><b>Darier J.</b> Lichen plan scl&eacute;reux. Ann
        Derm Syph 1892; 23: 833-7.</font></font></li>

        <li><a id="FN8" name="FN8"></a><font face="Arial"><font
        size="-1"><b>Unna PG.</b> Karenblattf&ouml;rmige
        sklerodermie. Lehrbuch der speziell path Anatomie (8 lief).
        Berlin: A Hirschwald, 1894: 112.</font></font></li>

        <li><a id="FN9" name="FN9"></a><font face="Arial"><font
        size="-1"><b>Westberg F.</b> Ein Fall von mit weissen
        flecken Einherhehender, bisher nicht bekannten Dermatose.
        Monatschr Prakt Dermatol 1901; 33:
        355-61.</font></font></li>

        <li><a id="FN10" name="FN10"></a><font face="Arial"><font
        size="-1"><b>Von Zombusch LR.</b> &Uuml;ber Lichen albus,
        eine bisher unbeschrieben Erkrankung. Arch Dermatol Syph
        (Berlin) 1906; 82: 339.</font></font></li>

        <li><a id="FN11" name="FN11"></a><font face="Arial"><font
        size="-1"><b>Montgomery FH, Ormsby OS.</b> "White spot
        disease" (morphea guttata) and lichen planus sclerosus et
        atrophicus. J Cutan Dis 1907; 25: 1-16.</font></font></li>

        <li><a id="FN12" name="FN12"></a><font face="Arial"><font
        size="-1"><b>Csillag J.</b> Dermatitis lichenoides chronica
        atrophicans. Ikonographia Dermatol 1909; 4:
        147.</font></font></li>

        <li><a id="FN13" name="FN13"></a><font face="Arial"><font
        size="-1"><b>Breisky A.</b> &Uuml;ber Kraurosis vulvae. Z
        Heilkr 1885; 6: 69.</font></font></li>

        <li><a id="FN14" name="FN14"></a><font face="Arial"><font
        size="-1"><b>St&uuml;hmer A.</b> Balanitis xerotica
        obliterans (post operationem) und ihre beziehungem zur
        Kraurosis glandis et preaeputii Penis. Arch Derm Syph
        (Berlin) 1928; 156: 613-23.</font></font></li>

        <li><a id="FN15" name="FN15"></a><font face="Arial"><font
        size="-1"><b>Friedrich EG.</b> Lichen sclerosus. J Reprod
        Med 1976; 17: 147-54.</font></font></li>

        <li><a id="FN16" name="FN16"></a><font face="Arial"><font
        size="-1"><b>Friedrich EG.</b> New nomenclature for vulvar
        disease. Obstet Gynecol 1976; 47: 122-4.</font></font></li>

        <li><a id="FN17" name="FN17"></a><font face="Arial"><font
        size="-1"><b>Gahan E.</b> Hallopeau's communications on
        lichen sclerosus et atrophicus. AMA Arch Dermatol Syphilol
        1954; 69: 435-7.</font></font></li>

        <li><a id="FN18" name="FN18"></a><font face="Arial"><font
        size="-1"><b>Miller RF.</b> Lichen sclerosus et atrophicus
        with oral involvement. AMA Arch Dermatol 1957;
        43-55.</font></font></li>

        <li><a id="FN19" name="FN19"></a><font face="Arial"><font
        size="-1"><b>Herzberg JJ, Meyer-Rohr J, Unna PJ.</b>
        Sclerolichen Gougerot. Arch Klin Exp Dermatol 1963; 216:
        246-59.</font></font></li>

        <li><a id="FN20" name="FN20"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Brookes DV,
        Sarkany I.</b> Lichen sclerosus et atrophicus with mouth
        lesions. Br J Dermatol 1970; 83: 422.</font></font></li>

        <li><a id="FN21" name="FN21"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Wallace HJ.</b>
        Lichen sclerosus et atrophicus. Trans St Johns Hosp Derm
        Soc 1971; 57: 9-30.</font></font></li>

        <li><a id="FN22" name="FN22"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Siar CH, Ng
        KH.</b> Oral lichen sclerosus et atrophicus. J Oral Med
        1985; 40: 148-50.</font></font></li>

        <li><a id="FN23" name="FN23"></a><font
        face="Arial,Helvetica"><font size="-1"><b>de Arujo VC,
        Orsini SC, Marcucci G, et al.</b> Lichen sclerosus et
        atrophicus. Oral Surg Oral Med Oral Pathol 1985; 60:
        655-7.</font></font></li>

        <li><a id="FN24" name="FN24"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dalziel K,
        Reynolds AJ, Holt PJA.</b> Lichen sclerosus et atrophicus
        with ocular and maxillary complications. Br J Dermatol
        1987; 116: 735-7.</font></font></li>

        <li><a id="FN25" name="FN25"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bousema MT,
        Romppanen U, Geiger J-M, et al.</b> Acitretin in the
        treatment of severe lichen sclerosus et atrophicus of the
        vulva: a double-blind, placebo-controlled study. J Am Acad
        Dermatol 1994; 30: 225-31.</font></font></li>

        <li><a id="FN26" name="FN26"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ravits HG, Welsh
        AL.</b> Lichen sclerosus et atrophicus of the mouth. AMA
        Arch Dermatol 1957; 76: 56-8.</font></font></li>

        <li><a id="FN27" name="FN27"></a><font
        face="Arial,Helvetica"><font size="-1"><b>McCarty L.</b>
        Circumscribed scleroderma [Comment]. Arch Dermatol Syphilil
        1939; 39: 904-7.</font></font></li>

        <li><a id="FN28" name="FN28"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ormsby OS,
        Mitchell JH.</b> Lichen planus atrophicus et sclerosus and
        kraurosis vulvae. Arch Derm Syph 1922; 5:
        786.</font></font></li>

        <li><a id="FN29" name="FN29"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Freeman C, Laymon
        CW.</b> <a
        href="/library/treatment/BXO/freeman1/">Balanitis xerotica
        obliterans</a>. Arch Dermatol Syphilol 1941; 44:
        547-61.</font></font></li>

        <li><a id="FN30" name="FN30"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Laymon CW,
        Freeman C.</b> <a
        href="/treatment/BXO/laymon1/">Relationship of balanitis
        xerotica obliterans to lichen sclerosus et atrophicus</a>.
        Arch Dermatol Syphilol 1944; 49: 57-9.</font></font></li>

        <li><a id="FN31" name="FN31"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ginsburg L.</b>
        Circumscribed scleroderma or leukoplakia of the vuvla in a
        child aged eight years. Arch Dermatol Syph 1939; 39:
        903.</font></font></li>

        <li><a id="FN32" name="FN32"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Aaronson LD,
        Baler G, Schiff BL.</b> Lichen sclerosus et atrophicus
        occurring in childhood. Arch Dermatol 1962; 85:
        746-7.</font></font></li>

        <li><a id="FN33" name="FN33"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dogliotti M,
        Bentley-Phillips CB, Schmaman A.</b> Lichen sclerosus et
        atrophicus in the Bantu. Br J Dermatol 1974; 91:
        81-5.</font></font></li>

        <li><a id="FN34" name="FN34"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Patel RI, Reed
        WB.</b> Annular atrophic plaques of the face and upper
        body. Cutis 1979; 24: 90-3.</font></font></li>

        <li><a id="FN35" name="FN35"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tagami H.</b>
        Eosinophilic infiltration in lichen sclerosus et atrophicus
        [Letter]. Arch Dermatol 1972; 105;
        606-7.</font></font></li>

        <li><a id="FN36" name="FN36"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bernstein JC,
        Robinson HM.</b> Circumscribed scleroderma. Arch Dermatol
        Syphilol 1939; 39: 904-7.</font></font></li>

        <li><a id="FN37" name="FN37"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jacyk WK, Isaac
        F.</b> Lichen sclerosus et atrophicus in Nigerians. J Natl
        Med Assoc 1979; 71: 387-8.</font></font></li>

        <li><a id="FN38" name="FN38"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ebert MH.</b> A
        case for diagnosis. Arch Dermatol Syphilol 1929; 19:
        144-5.</font></font></li>

        <li><a id="FN39" name="FN39"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Senear FE, Caro
        MR, Bucholz AM.</b> Lichen sclerosus et atrophicus. Arch
        Dermatol Syphilol. 1948; 57: 754-5.</font></font></li>

        <li><a id="FN40" name="FN40"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mowas CM, Guzzo
        CA.</b> A 14-year-old girl with hyperkeratotic plaques.
        Dermatol Today 1994; 4: 2-5.</font></font></li>

        <li><a id="FN41" name="FN41"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Woodruff JD,
        Baens JS.</b> Interpretation of atrophic and hydrothrophic
        alterations in the vulvar epithelium. Am J Obstet Gynecol
        1963; 86: 713-23.</font></font></li>

        <li><a id="FN42" name="FN42"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Brownstein
        MH.</b> Lichen sclerosus et atrophicus [Comment]. Arch
        Dermatol 1973; 108: 433.</font></font></li>

        <li><a id="FN43" name="FN43"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Helm KF, Gibson
        LE, Muller SA.</b> Lichen sclerosus et atrophicus in
        children and young adults. Pediatr Dermatol 1991; 8:
        97-101.</font></font></li>

        <li><a id="FN44" name="FN44"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Sherwood F, et al.</b> The lack of association
        of lichen sclerosus et atrophicus with HLA-A and B tissue
        antigens. Clin Exp Dermatol 1984; 9:
        290-2.</font></font></li>

        <li><a id="FN45" name="FN45"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Steigleder GK,
        Raab WP.</b> Lichen sclerosus et atrophicus. Arch Dermatol
        1961; 84: 219-26.</font></font></li>

        <li><a id="FN46" name="FN46"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Montgomery H,
        Hill WR.</b> Lichen sclerosus et atrophicus. Arch Dermatol
        1940; 42: 755-79.</font></font></li>

        <li><a id="FN47" name="FN47"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Oberfield RA.</b>
        Lichen sclerosus et atrophicus and kraurosis vulvae. Arch
        Dermatol 1962; 83: 144-53.</font></font></li>

        <li><a id="FN48" name="FN48"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Garcia-Bravo B,
        S&aacute;nchez-Pedreno P, Rodr&iacute;guez-Pichardo A, et
        al.</b> Lichen sclerosus et atrophicus. J Am Acad Dermatol
        1988; 19: 482-5.</font></font></li>

        <li><a id="FN49" name="FN49"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Crissey JT,
        Osborne ED, Jordon JW.</b> Lichen sclerosus et atrophicus
        in children. NY State J Med 1955; 55:
        2912-5.</font></font></li>

        <li><a id="FN50" name="FN50"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hyman AB, Falk
        HC.</b> White lesions of the vulva. Obstet Gynecol 1958;
        12: 407-13.</font></font></li>

        <li><a id="FN51" name="FN51"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hart WR, Norris
        HJ, Helwig EB.</b> Relation of lichen sclerosus et
        atrophicus of the vulva to development of carcinoma. Obstet
        Gynecol 1975; 45: 369-77.</font></font></li>

        <li><a id="FN52" name="FN52"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Loening-Baucke
        V.</b> Lichen sclerosus et atrophicus in children. Am J Dis
        Child 1991; 145: 1058-61.</font></font></li>

        <li><a id="FN53" name="FN53"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Chernosky MM,
        Derbes VJ, Burks JW.</b> Lichen sclerosus et atrophicus in
        children. Arch Dermatol 1957; 75:
        647-52.</font></font></li>

        <li><a id="FN54" name="FN54"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dalziel KL,
        Millard PR, Wojnarowska F.</b> The treatment of vulval
        lichen sclerosus with a very potent topical steroids
        (clobetasol proprionate 0.05%) cream. Br J Dermatol 1991;
        124: 461-4.</font></font></li>

        <li><a id="FN55" name="FN55"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Clark JS, Muller
        SA.</b> Lichen sclerosus et atrophicus in children. Arch
        Dermatol 1967; 95: 476-82.</font></font></li>

        <li><a id="FN56" name="FN56"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Laude TA,
        Narayanaswamy G, Rajkumar S.</b> Lichen sclerosus et
        atrophicus in an eleven year old girl. Cutis 1980; 26:
        78-80.</font></font></li>

        <li><a id="FN57" name="FN57"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Chalmers RJG,
        Burton PA, Bennet RF.</b> Lichen sclerosus et atrophicus.
        Arch Dermatol 1984; 120: 1025-7.</font></font></li>

        <li><a id="FN58" name="FN58"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Campus GV, Ena P,
        Scuderi N.</b> Surgical treatment of balanitis xerotica
        obliterans. Plast Reconstr Surg 1984; 73:
        652-7.</font></font></li>

        <li><a id="FN59" name="FN59"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ledwig PA,
        Weigand DA.</b> Late circumcision and lichen sclerosus et
        atrophicus of the penis. J Am Acad Dermatol 1989; 20:
        211-4.</font></font></li>

        <li><a id="FN60" name="FN60"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Schinella RA,
        Miranda D.</b> Posthitis xerotica obliterans in
        circumcision specimens. Urology 1974; 3:
        348-51.</font></font></li>

        <li><a id="FN61" name="FN61"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bainbridge DR,
        Whitaker RH, Shepheard BGF.</b> Balanitis xerotica
        obliterans and urinary obstruction. Br J Urol 1971; 43:
        487-91.</font></font></li>

        <li><a id="FN62" name="FN62"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Klenk-Pfeifer
        E.</b> Lichen sclerosus et atrophicus facei bei 12
        j&auml;hrigem M&auml;dchen. Z Hautkr 1974; 49:
        841.</font></font></li>

        <li><a id="FN63" name="FN63"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Foulds IS.</b>
        Lichen sclerosus et atrophicus of the scalp. Br J Dermatol
        1980; 103: 197-200.</font></font></li>

        <li><a id="FN64" name="FN64"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Purres J, Krull
        EA.</b> Lichen sclerosus et atrophicus involving the palms.
        Arch Dermatol 1971; 104: 68-9.</font></font></li>

        <li><a id="FN65" name="FN65"></a><font
        face="Arial,Helvetica"><font size="-1"><b>W&uuml;stner H,
        Gartmann H.</b> Palmoplantarar und genitoanaler lichen
        sclerosus et atrophicus bei einiigen Zwilligen. Z Hautkr
        1974; 49: 841-2.</font></font></li>

        <li><a id="FN66" name="FN66"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tudino ME, Wong
        AK.</b> Bullous lichen sclerosus et atrophicus on the palms
        and wrists. Cutis 1984; 33: 475-6.</font></font></li>

        <li><a id="FN67" name="FN67"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Petrozzi JW, Wood
        MG, Tisa V.</b> Palmar-plantar lichen sclerosus et
        atrophicus. Arch Dermatol 1979; 115:
        884.</font></font></li>

        <li><a id="FN68" name="FN68"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hammar H.</b>
        Plantar lesions of lichen sclerosus et atrophicus
        accompanied by erythermalgia. Acta Derm Venereol (Stockh)
        1978; 58: 91-2.</font></font></li>

        <li><a id="FN69" name="FN69"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Weigand DA.</b>
        Microscopic features of lichen sclerosus et atrophicus in
        acrochordons: A clue to the cause of lichen sclerosus et
        atrophicus? J Am Acad Dermatol 1993; 28:
        751-4.</font></font></li>

        <li><a id="FN70" name="FN70"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Fabry J.</b>
        &Uuml;ber einen fall von Kraurosis penis bei gleichzeitigem
        Bestehen von Weissflecken am Skrotum. Dermatol Wochnschr
        1928; 86: 7.</font></font></li>

        <li><a id="FN71" name="FN71"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mackee GM, Wise
        F.</b> White spot disease. J Cutan Dis 1914; 32:
        629-60.</font></font></li>

        <li><a id="FN72" name="FN72"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Laymon CW.</b>
        Lichen sclerosus et atrophicus and related disorders. Arch
        Dermatol 1951; 64: 620-7.</font></font></li>

        <li><a id="FN73" name="FN73"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Borda JM,
        Abulafia J, Jaimovich L.</b> Syndrome of circumscribed
        sclero-atrophies. Derm Ibero Lat Am 1968; 3:
        179-202.</font></font></li>

        <li><a id="FN74" name="FN74"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Johnston JC,
        Sherwell S.</b> White spot disease. J Cutan Dis 1903; 21:
        302-7.</font></font></li>

        <li><a id="FN75" name="FN75"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Edwards NW,
        Arnold HL.</b> Corymbiform lichen sclerosus et atrophicus.
        Arch Dermatol 1979; 115: 1035.</font></font></li>

        <li><a id="FN76" name="FN76"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mopper C,
        Courville C, Hendren O.</b> Lichen sclerosus et atrophicus.
        Arch Dermatol 1956; 73: 611-3.</font></font></li>

        <li><a id="FN77" name="FN77"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Barclay DL, Macey
        HB, Reed RJ.</b> Lichen sclerosus et atrophicus of the
        vulva in children. Obstet Gynecol 1966; 27:
        637-42.</font></font></li>

        <li><a id="FN78" name="FN78"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman RH,
        Friedrich EG, Gardner HC.</b> Benign diseases of the vulva
        and vagina. Chicago: Year Book Medical Publishers, 1989:
        302-23.</font></font></li>

        <li><a id="FN79" name="FN79"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Wallace HJ,
        Whimster IW.</b> Vulval atrophy and leukoplakia. Br J
        Dermatol 1951; 63: 241-57.</font></font></li>

        <li><a id="FN80" name="FN80"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kindler T.</b>
        Lichen sclerosus et atrophicus in young subjects. Br J
        Dermatol 1953; 269-79.</font></font></li>

        <li><a id="FN81" name="FN81"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Klein LE, Cohen
        SR, Weinstein M.</b> Bullous lichen sclerosus et
        atrophicus: treatment by tangential excision. J Am Acad
        Dermatol 1984; 10: 346-50.</font></font></li>

        <li><a id="FN82" name="FN82"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Penneys NS.</b>
        Treatment of lichen sclerosus with potassium
        para-aminobenzoate. J Am Acad Dermatol 1984; 10:
        1039-42.</font></font></li>

        <li><a id="FN83" name="FN83"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Di Silverio A,
        Serri F.</b> Generalized bullous and haemorrhagic lichen
        sclerosus et atrophicus. Br J Dermatol 1975; 93:
        215-7.</font></font></li>

        <li><a id="FN84" name="FN84"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Gottschalk HR,
        Copper ZK.</b> Lichen sclerosus et atrophicus with bullous
        lesions and extensive involvement. Arch Dermatol Syph 1947;
        55: 433-40.</font></font></li>

        <li><a id="FN85" name="FN85"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Apisarnthanarax
        P, Osment LS, Montes LF.</b> Extensive lichen sclerosus et
        atrophicus in a 7-year-old boy. Arch Dermatol 1972; 106:
        94-6.</font></font></li>

        <li><a id="FN86" name="FN86"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Templeton HJ.</b>
        Localized scleroderma with bullae. Arch Dermatol Syph 1941;
        43: 361-5.</font></font></li>

        <li><a id="FN87" name="FN87"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pasieczny
        TAH.</b> <a href="/library/treatment/BXO/pasieczny1/">The
        treatment of balanitis xerotica obliterans with
        testosterone propionate ointment</a>. Acta Derm Venereol
        (Stockh) 1977; 57: 275-7.</font></font></li>

        <li><a id="FN88" name="FN88"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Staff WG.</b>
        Urethral involvement in balanitis xerotica obliterans. Br J
        Urol 1970; 47: 234-9.</font></font></li>

        <li><a id="FN89" name="FN89"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Chalmers RJG,
        Burton PA, Bennett R, et al.</b> Lichen sclerosus et
        atrophicus: a distinctive and common cause of phimosis in
        boys. Br J Dermatol 1982; 107 (suppl):
        29-30.</font></font></li>

        <li><a id="FN90" name="FN90"></a><font
        face="Arial,Helvetica"><font size="-1"><b>J&auml;nner M,
        Sch&uuml;tte B, Breitbart E.</b> Lichen sclerosus et
        atrophicus penis bei pr&auml;pubertaeren knaben. Z Hautkr
        1978; 53: 923-8.</font></font></li>

        <li><a id="FN91" name="FN91"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Anderton Rl,
        Abele DC.</b> Lichen sclerosus et atrophicus in a
        vaccination site [Letter]. Arch Dermatol 1976; 112:
        1787.</font></font></li>

        <li><a id="FN92" name="FN92"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG.</b>
        <i>Vulvar disease.</i> Philadelphia: WB Saunders, 1983:
        71-4, 129-42.</font></font></li>

        <li><a id="FN93" name="FN93"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taussig FJ.</b>
        Chronic leukoplakic vulvitis followed by cancer. Surg Clin
        North Am 1922; 2: 1559-70.</font></font></li>

        <li><a id="FN94" name="FN94"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Barker LP, Gross
        P.</b> Lichen sclerosus et atrophicus of the female
        genitalia. Arch Dermatol 1962; 85:
        362-73.</font></font></li>

        <li><a id="FN95" name="FN95"></a><font
        face="Arial,Helvetica"><font size="-1"><b>T&ouml;r&ouml;k
        E, &Ouml;rley J, G&ouml;r&aacute;cz G, et al.</b> Lichen
        sclerosus et atrophicus in children. Mod Probl Paediatr
        1975; 17: 262-71.</font></font></li>

        <li><a id="FN96" name="FN96"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Berth-Jones J,
        Graham-Brown RAC, Burns DA.</b> Lichen sclerosus et
        atrophicus: a review of 15 cases in young girls. Clin Exp
        Dermatol 1991; 16: 14-7.</font></font></li>

        <li><a id="FN97" name="FN97"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jenny C, Kirby P,
        Furquay D.</b> Genital lichen sclerosus mistaken for child
        sexual abuse. Pediatrics 1981; 83:
        597-9.</font></font></li>

        <li><a id="FN98" name="FN98"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Handfield-Jones
        SE, Hinde FRJ, Kennedy CT.</b> Lichen sclerosus et
        atrophicus in children misdiagnosed as sexual abuse. Br Med
        J 1987; 294: 1404-5.</font></font></li>

        <li><a id="FN99" name="FN99"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Priestley BL,
        Bleehen SS.</b> Lichen sclerosus et atrophicus in children
        misdiagnosed as sexual abuse [Letter]. Br Med J 1987; 295:
        211.</font></font></li>

        <li><a id="FN100" name="FN100"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Davidson DC,
        Clarke MDB, Kean HB.</b> Lichen sclerosus et atrophicus in
        children misdiagnosed as sexual abuse [Letter]. Br Med J
        1987; 295: 211.</font></font></li>

        <li><a id="FN101" name="FN101"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Berth-Jones J,
        Graham-Brown EAC, Burns DA.</b> Lichen sclerosus. Arch Dis
        Child 1989; 64: 1204-6.</font></font></li>

        <li><a id="FN102" name="FN102"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ridley CM.</b>
        Lichen sclerosus et atrophcius. Semin Dermatol 1989; 8:
        54-63.</font></font></li>

        <li><a id="FN103" name="FN103"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ridley CM.</b>
        Genital lichen sclerosus (lichen sclerosus et atrophicus)
        in childhood and adolescence. J R Soc Med 1993; 86:
        69-75.</font></font></li>

        <li><a id="FN104" name="FN104"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Priestley BL,
        Bleehen SS.</b> Lichen sclerosus and sexual abuse. Arch Dis
        Child 1990; 65: 335.</font></font></li>

        <li><a id="FN105" name="FN105"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Helm KF, Gibson
        LE, Muller SA.</b> Lichen sclerosus et atrophicus in
        children and young adults. Pediatr Dermatol 1991; 8:
        97-101.</font></font></li>

        <li><a id="FN106" name="FN106"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ditkowsky SP,
        Falk AB, Baker N, et al.</b> Lichen sclerosus et atrophicus
        in childhood. Am J Dis Child 1956; 91:
        52-4.</font></font></li>

        <li><a id="FN107" name="FN107"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Huffman JW.</b>
        Vulvar disorders in premenarchal children. Clin Obstet
        Gynecol 1960; 31: 154-63.</font></font></li>

        <li><a id="FN108" name="FN108"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Sanchez NP, Mihm
        MC.</b> Reactive and neoplastic epithelial alterations of
        the vuvla. J Am Acad Dermatol 1982; 6:
        378-88.</font></font></li>

        <li><a id="FN109" name="FN109"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Madden JF.</b>
        The balanitides. JAMA 1935; 105: 420-7.</font></font></li>

        <li><a id="FN110" name="FN110"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Black MM.</b> Clinical features and therapy of
        lichen sclerosus et atrophicus affecting males. Clin Exp
        Dermatol 1987; 12: 126-8.</font></font></li>

        <li><a id="FN111" name="FN111"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Weitzner S.</b>
        Posthitis xerotica obliterans. Am J Dis Child 1972; 123:
        68-9.</font></font></li>

        <li><a id="FN112" name="FN112"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Potter B.</b>
        Balanitis xerotica obliterans manifesting on stump of
        amputated penis. Arch Dermatol 1959; 79:
        473-6.</font></font></li>

        <li><a id="FN113" name="FN113"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mckay DL, Fuqua
        F, Weinberg AG.</b> <a
        href="/library/treatment/BXO/mckay1/">Balanitis xerotica
        obliterans in children</a>. J Urol 1975; 114:
        773-5.</font></font></li>

        <li><a id="FN114" name="FN114"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bale PM, Lochhead
        A, Martin HCO, et al.</b> Balanitis xerotica obliterans in
        children. Pediatr Pathol 1987; 7:
        617-27.</font></font></li>

        <li><a id="FN115" name="FN115"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Whimster IW.</b>
        The natural history of skin malignancy. Br J Dermatol 1965;
        77: 534-5.</font></font></li>

        <li><a id="FN116" name="FN116"></a><font
        face="Arial,Helvetica"><font size="-1"><b>di Paola GR,
        Rueda-Leverone NG, Belardi MG.</b> Lichen sclerosus of the
        vulva recurrent after myocutaneous graft. J Reprod Med
        1982; 27: 666-8.</font></font></li>

        <li><a id="FN117" name="FN117"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Adair Fl, Davis
        ME, Schuitema DM.</b> Atrophy of the vulva. JAMA 1950; 114:
        296-303.</font></font></li>

        <li><a id="FN118" name="FN118"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Montgomery H.</b>
        Lichen sclerosus et atrophicus [Comment]. Arch Dermatol
        Syph 1951; 64: 654-5.</font></font></li>

        <li><a id="FN119" name="FN119"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jeffcoate
        TNA.</b> Chronic vulvar dystrophies. Am J Obstet Gynecol
        1966; 95: 61-74.</font></font></li>

        <li><a id="FN120" name="FN120"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cockerell EG,
        Knox JM, Rogers SF.</b> Lichen sclerosus et atrophicus.
        Obstet Gynecol 1960; 15: 554-9.</font></font></li>

        <li><a id="FN121" name="FN121"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG.</b>
        Vulvar dystrophy. Clin Obstet Gynecol 1985; 28:
        178-87.</font></font></li>

        <li><a id="FN122" name="FN122"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Barker LP, Gross
        P.</b> Lichen sclerosus et atrophicus of the female
        genitalia. Arch Dermatol 1962; 85:
        102-13.</font></font></li>

        <li><a id="FN123" name="FN123"></a><font
        face="Arial,Helvetica"><font size="-1"><b>McAdams AJ,
        Kirstner RW.</b> The relationship of chronic vulvar
        disease, leukoplakia, and carcinoma in situ to carcinoma of
        the vulva. Cancer 1958; 11: 740-57.</font></font></li>

        <li><a id="FN124" name="FN124"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Panet-Raymond G,
        Dirard C.</b> Lichen sclerosus et atrophicus. Can Med J
        1972; 106: 1332-4.</font></font></li>

        <li><a id="FN125" name="FN125"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taylor H.</b>
        Leukoplakia of the vulva [Comment]. Am J Obstet Gynecol
        1952; 64: 778.</font></font></li>

        <li><a id="FN126" name="FN126"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pock L.</b>
        Koebner phenomenon in lichen sclerosus et atrophicus.
        Dermatologica 1990; 181: 76-7.</font></font></li>

        <li><a id="FN127" name="FN127"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pass CJ.</b> An
        unusual variant of lichen sclerosus et atrophicus: delayed
        appearance in a surgical scar. Cutis 1984; 33:
        405-6.</font></font></li>

        <li><a id="FN128" name="FN128"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rothman S.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol 1957; 75:
        294.</font></font></li>

        <li><a id="FN129" name="FN129"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Yates VM, King
        CM, Dave VK.</b> Lichen sclerosus et atrophicus following
        radiation therapy. Arch Dermatol 1985; 121:
        1044-7.</font></font></li>

        <li><a id="FN130" name="FN130"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Milligan A,
        Graham-Brown RA, Burns DA.</b> Lichen sclerosus et
        atrophicus following sunburn. Clin Exp Dermatol 1988; 13:
        36-7.</font></font></li>

        <li><a id="FN131" name="FN131"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Meffert JJ,
        Grimwood RR.</b> Lichen sclerosus et atrophicus appearing
        in an old burn scar. J Am Acad Dermatol 1994; 31:
        671-3.</font></font></li>

        <li><a id="FN132" name="FN132"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kahana M, Levy A,
        Schewach-Millet M, et al.</b> Appearance of lupus
        erythematosus in a patient with lichen sclerosus et
        atrophicus of the elbows [Letter]. J Am Acad Dermatol 1985;
        12: 127-9.</font></font></li>

        <li><a id="FN133" name="FN133"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ronnen M, Suster
        S, Kahana M, et al.</b> Bilateral Koebner phenomenon in
        lichen sclerosus et atrophicus. Int J Dermatol 1987; 26:
        117-8.</font></font></li>

        <li><a id="FN134" name="FN134"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Gross P.</b>
        Generalized lichen sclerosus et atrophicus associated with
        band-like scleroderma (Koebner phenomenon and lichen
        sclerosus). Arch Dermatol 1958; 77:
        752-3.</font></font></li>

        <li><a id="FN135" name="FN135"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Schamberg JF,
        Hirschler R.</b> Lichen planus sclerosus. JAMA 1909; 53:
        369-73.</font></font></li>

        <li><a id="FN136" name="FN136"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ormsby OS.</b>
        Lichen planus atrophicus (Hallopeau). J Cutan Dis 1910; 28:
        460.</font></font></li>

        <li><a id="FN137" name="FN137"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taylor HC.</b>
        Leukoplakia of the vulva [Comment]. Am J Obstet Gynecol
        1947; 54: 560.</font></font></li>

        <li><a id="FN138" name="FN138"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hewitt J.</b>
        Histologic criteria for lichen sclerosus of the vulva. J
        Reprod Med 1986; 31: 781-7.</font></font></li>

        <li><a id="FN139" name="FN139"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ackerman AB.</b>
        Histologic diagnosis of inflammatory skin diseases.
        Philadelphia: Lea &amp; Febiger, 1978: 198-202,
        760-5.</font></font></li>

        <li><a id="FN140" name="FN140"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ackerman AB.</b>
        The lives of lesions. Philadelphia: Lea &amp; Febiger,
        1984: 131-7, 194-201.</font></font></li>

        <li><a id="FN141" name="FN141"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jablonska SI.</b>
        Scleroderma and pseudoscleroderma. Warsaw: Panstwowy Zalkad
        Lekarskich, 1965: 265-76.</font></font></li>

        <li><a id="FN142" name="FN142"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Barbero M,
        Micheletti L, Borgno G, et al.</b> Vulvar dystrophies in
        young and premenopausal women. J Reprod Med 1988; 33:
        555-8.</font></font></li>

        <li><a id="FN143" name="FN143"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG,
        MacLaren NK.</b> Genetic aspects of vulvar lichen
        sclerosus. Am J Obstet Gynecol 1984; 150:
        161-6.</font></font></li>

        <li><a id="FN144" name="FN144"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Shelley WB, Levy
        EJ.</b> Histologic observations on the human apocrine sweat
        gland in health and disease. J Invest Dermatol 1955; 25:
        249-63.</font></font></li>

        <li><a id="FN145" name="FN145"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Stoughton R,
        Wells G.</b> A histochemical study on polysaccharides in
        normal and diseased skin. J Invest Dermatol 1950; 14:
        37-51.</font></font></li>

        <li><a id="FN146" name="FN146"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Frances C,
        Wechsler J, Meimon G, et al.</b> Investigation of
        intercellular matrix macromolecules involved in lichen
        sclerosus. Acta Derm Venereol (Stockh) 1983; 63:
        483-90.</font></font></li>

        <li><a id="FN147" name="FN147"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Suurmond D.</b>
        Lichen sclerosus et atrophicus of the vulva. Arch Dermatol
        1964; 90: 143-52.</font></font></li>

        <li><a id="FN148" name="FN148"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ackerman AB,
        Niven J, Grant-Kels JM.</b> Differential diagnosis in
        dermatopathology. Philadelphia: Lea &amp; Fabiger, 1982:
        62-5.</font></font></li>

        <li><a id="FN149" name="FN149"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Romppanen U,
        Rantala I, Lauslahti K, et al.</b> Light and electron
        microscope findings in lichen sclerosus of the vulva during
        etretinate treatment. Dermatologica 1987; 175:
        33-40.</font></font></li>

        <li><a id="FN150" name="FN150"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rahbari H.</b>
        Histochemical differentiation of localized
        morphea-scleroderma and lichen sclerosus et atrophicus. J
        Cutan Pathol 1989; 16: 342-7.</font></font></li>

        <li><a id="FN151" name="FN151"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Winer LH.</b>
        Elastic fibers in unusual dermatoses. Arch Dermatol 1955;
        71: 338-48.</font></font></li>

        <li><a id="FN152" name="FN152"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ketron W, Ellis
        FA.</b> Kraurosis vulvae and white spot scleroderma. Arch
        Dermatol Syph 1939; 39: 904.</font></font></li>

        <li><a id="FN153" name="FN153"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mann PR, Cowan
        MA.</b> Ultrastructural changes in four cases of lichen
        sclerosus et atrophicus. Br J Dermatol 1973; 89:
        223-31.</font></font></li>

        <li><a id="FN154" name="FN154"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dar&oacute;czy J,
        T&ouml;r&ouml;k E.</b> Electronmicroscopy of lichen
        sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc
        1974; 60: 183-7.</font></font></li>

        <li><a id="FN155" name="FN155"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Forsman WG,
        Holzmann H, Cabre J.</b> Elektronenmikroskopische
        Untersuchungen der Haut beim Lichen Sclerosus et
        Atrophicans. Arch Klin Exp Dermatol 1964; 220:
        584-99.</font></font></li>

        <li><a id="FN156" name="FN156"></a><font
        face="Arial,Helvetica"><font size="-1"><b>S&aacute;nchez E,
        Aguilar A, Requena L, et al.</b> Nevus elasticus and lichen
        sclerosus et atrophicus on the vulva. Cutis 1990; 45:
        252-5.</font></font></li>

        <li><a id="FN157" name="FN157"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Asbrink E,
        Hovmark A.</b> Cutaneous manifestations in
        <i>Ixodes-</i>borne <i>Borrelia</i> spirochetosis. Int J
        Dermatol 1987; 26: 215-23.</font></font></li>

        <li><a id="FN158" name="FN158"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ketron LW, Ellis
        FA.</b> Kraurosis vulvae (leucoplacia) and scleroderma
        circumscripta. Surg Gynecol Obstet 1935; 61:
        635-50.</font></font></li>

        <li><a id="FN159" name="FN159"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Janovski NA, Ames
        S.</b> Lichen sclerosus et atrophicus of the vulva: a
        poorly understood disease entity. Obstet Gynecol 1963; 22:
        697-708.</font></font></li>

        <li><a id="FN160" name="FN160"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lascano EF,
        Montes LF, Mazzini MA.</b> Lichen sclerosus et atrophicus
        in childhood. Obstet Gynecol 1964; 24:
        872-7.</font></font></li>

        <li><a id="FN161" name="FN161"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pawlowski A.</b>
        The nerve network of the skin in diffuse scleroderma and
        clinically similar conditions. Arch Dermatol 1963; 88:
        236-41.</font></font></li>

        <li><a id="FN162" name="FN162"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Leppard B,
        Sneddon IB.</b> Milia occurring in lichen sclerosus et
        atrophicus. Br J Dermatol 1975; 92:
        711-4.</font></font></li>

        <li><a id="FN163" name="FN163"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Garat JM,
        Ch&eacute;chile G, Algaba F, et al.</b> Balanitis xerotica
        obliterans in children. J urol 1986; 136:
        436-7.</font></font></li>

        <li><a id="FN164" name="FN164"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Leifer W.</b>
        Balanitis xerotica obliterans. Arch Dermatol Syph. 1944;
        49: 118-9.</font></font></li>

        <li><a id="FN165" name="FN165"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Catterall RD,
        Oates JK.</b> Treatment of balanitis xerotica obliterans
        with hydrocortisone injections. Br J Vener Dis 1962; 38:
        75-7.</font></font></li>

        <li><a id="FN166" name="FN166"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Shapiro L.</b>
        Lichen sclerosus et atrophicus: first reported case in a
        boy. Dermatologica 1968; 136: 155-9.</font></font></li>

        <li><a id="FN167" name="FN167"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mikat DM,
        Ackerman HR, Mikat KW.</b> Balanitis xerotica obliterans:
        report of a case in an 11-year-old and review of the
        literature. Pediatrics 1973; 52: 41-4.</font></font></li>

        <li><a id="FN168" name="FN168"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Clemmensen OJ,
        Krogh J, Petri M.</b> The histologic&nbsp; spectrum of
        prepuces from patients with phimosis. Am J Dermatopathol
        1988; 10: 104-8.</font></font></li>

        <li><a id="FN169" name="FN169"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Gairdner D.</b>
        <a href="/library/general/gairdner/">The fate of the
        foreskin</a>. Br Med J 1949; 2: 1433-7.</font></font></li>

        <li><a id="FN170" name="FN170"></a><font
        face="Arial,Helvetica"><font size="-1"><b>&Oslash;ster
        J.</b> <a href="/library/general/oster/">Further fate of
        the foreskin</a>. Arch Dis Child 1968; 43:
        200-3.</font></font></li>

        <li><a id="FN171" name="FN171"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Spicer RD.</b>
        Genital lichen sclerosus et atrophicus. J R Soc Med 1993;
        86: 556.</font></font></li>

        <li><a id="FN172" name="FN172"></a><font
        face="Arial,Helvetica"><font size="-1"><b>J&oslash;rgensen
        ET, Svensson A.</b> <a
        href="/library/treatment/phimosis/jorgensen/">The treatment
        of phimosis in boys, with a potent topical steroid
        (clobetasol proprionate 0.05%) cream</a>. Acta Derm
        Venereol (Stockh) 1993; 73: 55-6.</font></font></li>

        <li><a id="FN173" name="FN173"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rickwood AMK,
        Hemalatha V, Batcup G, et al.</b> <a
        href="/library/treatment/phimosis/rickwood/">Phimosis in
        boys</a>. Br J Urol 1980; 50: 147-50.</font></font></li>

        <li><a id="FN174" name="FN174"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pride HB, Miller
        OF III, Tyler WB.</b> Penile squamous cell carcinoma
        arising from balanitis xerotica obliterans. J Am Acad
        Dermatol 1993; 29: 469-73.</font></font></li>

        <li><a id="FN175" name="FN175"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bingham JS.</b>
        Carcinoma of the penis developing lichen sclerosus et
        atrophicus. Br J vener Dis 1978; 54:
        350-1.</font></font></li>

        <li><a id="FN176" name="FN176"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Weigand DA.</b>
        Lichen sclerosus et atrophicus, multiple dysplastic
        keratoses and squamous cell carcinoma of the glans penis. J
        Dermatol Surg Oncol 1980; 6: 45-50.</font></font></li>

        <li><a id="FN177" name="FN177"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bart RS, Kopf
        AW.</b> Squamous cell carcinoma arising in balanitis
        xerotica obliterans. J Dermatol Surg Oncol 1978; 4:
        556-8.</font></font></li>

        <li><a id="FN178" name="FN178"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Weber P,
        Rabinowitz H, Garland L.</b> Verrucous carcinoma in penile
        lichen sclerosus et atrophicus. J Dermatol Surg Oncol 1978;
        13: 529-32.</font></font></li>

        <li><a id="FN179" name="FN179"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Reid R, Greenberg
        MD, Daoud Y, et al.</b> Colposcopic findings in women with
        vulvar pain syndromes. J Reprod Med 1988; 33:
        523-32.</font></font></li>

        <li><a id="FN180" name="FN180"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rodke G,
        Friedrich EF, Wilkinson EJ.</b> Malignant potential of
        mixed vulvar dystrophy (lichen sclerosus associated with
        squamous cell hyperplasia). J Reprod Med 1988; 33:
        545-50.</font></font></li>

        <li><a id="FN181" name="FN181"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ridley CM,
        Frankman O, Jones ISC, et al.</b> New nomenclature for
        vulvar disease. Am J Obstet Gynecol 1989; 160:
        769.</font></font></li>

        <li><a id="FN182" name="FN182"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Gardner HL,
        Friedrich EG, Kaufman RH, et al.</b> The vulvar
        dystrophies, atypias, and carcinomata in situ: an
        invitational symposium. J Reprod Med 1976; 17:
        131-6.</font></font></li>

        <li><a id="FN183" name="FN183"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taussig FJ.</b>
        Precancerous lesions of the skin of the vulva. Arch
        Dermatol Syph 1920; 1: 621-35.</font></font></li>

        <li><a id="FN184" name="FN184"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taussig FJ.</b>
        Leukoplakic vulvitis and cancer of the vulva (etiology,
        histopathology, treatment, five-year results). Am J Obstet
        Gynecol 1929; 18: 472-503.</font></font></li>

        <li><a id="FN185" name="FN185"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Taussig FJ.</b>
        Cancer of the vulva. Am J Obstet Gynecol 1940; 40:
        764-79.</font></font></li>

        <li><a id="FN186" name="FN186"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Parks J.</b>
        Similarity of mouth and vulvar lesions. Am J Obstet Gynecol
        1945; 49: 396-400.</font></font></li>

        <li><a id="FN187" name="FN187"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman RH.</b>
        Hyperplastic dystrophy. J Reprod Med 1976; 17:
        137-45.</font></font></li>

        <li><a id="FN188" name="FN188"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Franks AG.</b>
        Balanitis xerotica obliterans. J Urol 1946; 56:
        243-5.</font></font></li>

        <li><a id="FN189" name="FN189"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, McGibbon DH, et al.</b> Lichen sclerosus et
        atrophicus and autoimmunity: a study of 350 women. Br J
        Dermatol 1988; 118: 41-6.</font></font></li>

        <li><a id="FN190" name="FN190"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Miller NF,
        Parrott MH, Stryker J, et al.</b> Leucoplakia of the vulva.
        Am J Obstet Gynecol 1947; 54: 543-60.</font></font></li>

        <li><a id="FN191" name="FN191"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Newbold PCH.</b>
        Pre-cancer and the skin. Br J Dermatol 1972; 86:
        417-34.</font></font></li>

        <li><a id="FN192" name="FN192"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Davis ME.</b> The
        differential diagnosis and treatment of vulvar lesions.
        Surg Clin North Am 1950; 30: 267-86.</font></font></li>

        <li><a id="FN193" name="FN193"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Graves WP, Smith
        GVS.</b> Kraurosis vulvae. JAMA 1929; 92:
        1244-52.</font></font></li>

        <li><a id="FN194" name="FN194"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Healy WP.</b>
        Leukoplakia of the vulva [Comment]. Am J Obstet Gynecol
        1947; 54: 559.</font></font></li>

        <li><a id="FN195" name="FN195"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Langley II,
        Hertig AT, Smith GVS.</b> Relation of leucoplakic vulvitis
        to squamous cell carcinoma of the vulva. Am J Obstet
        Gynecol 1951; 62: 167-9.</font></font></li>

        <li><a id="FN196" name="FN196"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Camacho-Martinez
        F, navarro J, Moreno JC, et al.</b> International
        dermatosurgery: reconstructive treatment of the
        vulva&mdash;a new procedure. J Dermatol Surg Oncol 1987;
        13: 488-94.</font></font></li>

        <li><a id="FN197" name="FN197"></a><font
        face="Arial,Helvetica"><font size="-1"><b>August PJ,
        Milward TM.</b> Cryosurgery in the treatment of lichen
        sclerosus et atrophicus of the vulva. Br J Dermatol 1980;
        103: 667-70.</font></font></li>

        <li><a id="FN198" name="FN198"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cario GM. House
        MJ, Paradinas FJ.</b> Squamous cell carcinoma of the vulva
        in association with mixed vulvar dystrophy in an
        18-year0old girl. Br J Obstet Gynaecol 1984; 91:
        87-90.</font></font></li>

        <li><a id="FN199" name="FN199"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jeffcoate TNA,
        Woodcok AS.</b> Premalignant conditions of the vulva, with
        particular reference to chronic epithelial dystrophies. Br
        Med J 1961; 2: 127-34.</font></font></li>

        <li><a id="FN200" name="FN200"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Woodruff JD.</b>
        Vulvar atypia and carcinoma in situ. J Reprod Med 1976; 17:
        155-63.</font></font></li>

        <li><a id="FN201" name="FN201"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman RH,
        Gardner HL, Brown D, et al.</b> Vulvar dystrophies: an
        evaluation. Am J Obstet Gynecol 1974; 120:
        363-7.</font></font></li>

        <li><a id="FN202" name="FN202"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cockerell EG,
        Knox JM, Rogers SF.</b> Lichen sclerosus et atrophicus.
        Obstet Gynecol 1960; 15: 554-9.</font></font></li>

        <li><a id="FN203" name="FN203"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Woodruff JD,
        Borkowf HI, Holzman GB, et al.</b> Metabolic activity in
        normal and abnormal vulvar epithelia. Am J Obstet Gynecol
        1965; 91: 809-19.</font></font></li>

        <li><a id="FN204" name="FN204"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Clark DGC, Zumoff
        B, Brunschwig A, et al.</b> Preferential uptake of
        phosphate by premalignant and malignant lesions of the
        vulva. Cancer 1960; 13: 775-9.</font></font></li>

        <li><a id="FN205" name="FN205"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG,
        Julian CG, Woodruff JD.</b> Acridine orange fluorescence in
        vulvar dysplasia. Am J Obstet Gynecol 1964; 90:
        1281-7.</font></font></li>

        <li><a id="FN206" name="FN206"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Newton JA,
        Camplejohn RS, McGibbin DH.</b> A flow cytometric study of
        the significance of DNA aneuploidy in cutaneous lesions. Br
        J Dermatol 1987; 117: 169-74.</font></font></li>

        <li><a id="FN207" name="FN207"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman RH,
        Gardner HL, Johnson PC.</b> P</font><sup><font
        size="-2">32</font></sup><font size="-1">uptake in lichen
        sclerosus et atrophicus of the vulva. Am J Obstet Gynecol
        1967; 98: 312-9.</font></font></li>

        <li><a id="FN208" name="FN208"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Woodruff JD.</b>
        Carcinoma in situ of the vulva. Clin Obstet Gynecol 1985;
        28: 230-9.</font></font></li>

        <li><a id="FN209" name="FN209"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Buscema J, Stern
        J, Woodruff JD.</b> The significance of the histologic
        alterations adjacent to invasive vulvar carcinoma. Am J
        Obstet Gynecol 1980; 137: 902-9.</font></font></li>

        <li><a id="FN210" name="FN210"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Reid P.</b>
        Physical and surgical principles governing expertise with
        the carbon dioxide laser. Obstet Gynecol Clin North Am
        1987; 14: 513-35.</font></font></li>

        <li><a id="FN211" name="FN211"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Soper JT,
        Creaseman WT.</b> Vulvar dystrophies. Clin Obstet Gynecol
        1986; 29: 431-9.</font></font></li>

        <li><a id="FN212" name="FN212"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Reid R, Elfont
        EA, Zirkin EM, et al.</b> Superficial laser vulvectomy. Am
        J Obstet Gynecol 1985; 152: 261-71.</font></font></li>

        <li><a id="FN213" name="FN213"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Collins CG,
        Hansen LH, Theriot E.</b> A clnical stain for use in
        selecting biopsy sites in patients with vulvar disease.
        Obstet Gynecol 1966; 28: 158-63.</font></font></li>

        <li><a id="FN214" name="FN214"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        McGibbon, Munro DD.</b> Basal cell carcinoma of the vulva
        in associaiton with vulval lichen sclerosus et atrophicus.
        J R Soc Med 1985; 78 (suppl 11): 16-8.</font></font></li>

        <li><a id="FN215" name="FN215"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedman RJ, Kopf
        AW, Jones WB.</b> Malignant melanoma in association with
        lichen sclerosus on the vulva of a 14-year-old. Am J
        Dermatopathol 1984; 6 (suppl 1): 253-6.</font></font></li>

        <li><a id="FN216" name="FN216"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Wise F, Shelmire
        B.</b> Chronic atrophic lichenoid dermatitis (Csillag).
        Arch Dermatol Syph 1928; 18: 179-99.</font></font></li>

        <li><a id="FN217" name="FN217"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Shirer JA, Ray
        MC.</b> Familial occurrence of lichen sclerosus et
        atrophicus. Arch Dermatol 1987; 123:
        485-8.</font></font></li>

        <li><a id="FN218" name="FN218"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ormsby OS.</b>
        Lichen planus sclerosus et atrophicus (Hallopeau). JAMA
        1910; 55: 901-6.</font></font></li>

        <li><a id="FN219" name="FN219"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Miller JL.</b>
        Scleroderma en bande and lichen sclerosus et atrophicus.
        Arch Dermatol 1957; 76: 144-5.</font></font></li>

        <li><a id="FN220" name="FN220"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mensing H,
        Schmidt KU.</b> Diffuse fasciitis with eosinophilia
        associated with morphea and lichen sclerosus et atrophicus.
        Acta Derm Venereol (Stockh) 1985; 65:
        80-3.</font></font></li>

        <li><a id="FN221" name="FN221"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tafelkruyer J,
        Claessens FLE.</b> Lichen sclerosus et atrophicus and
        scleroderma circumscripta. Dermatologica 1978; 156:
        313-6.</font></font></li>

        <li><a id="FN222" name="FN222"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Connelly MG,
        Winkelmann RK.</b> Coexistence of lichen sclerosus,
        morphea, and lichen planus. J Am Acad Dermatol 1985; 12:
        844-51.</font></font></li>

        <li><a id="FN223" name="FN223"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Black MM.</b> Lichen sclerosus et atrophicus
        associated with systemic lupus erythematosus [Letter]. J Am
        Acad Dermatol 1985; 13: 832.</font></font></li>

        <li><a id="FN224" name="FN224"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tremaine R, Adam
        JE, Orizaga M.</b> Morphea coexisting with lichen sclerosus
        et atrophicus. Int J Dermatol 1990; 29:
        486-9.</font></font></li>

        <li><a id="FN225" name="FN225"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hauser W.</b> Zur
        nosologischen Stellung des Lichen Sclerosus et Atrophicus.
        Arch Klin Exp Dermatol 1958; 208: 44-52.</font></font></li>

        <li><a id="FN226" name="FN226"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Natarajan S,
        Green ST.</b> Generalized morphoea, lichen sclerosus et
        atrophicus, and primary biliary cirrhosis. Clin Exp
        Dermatol 1986; 11: 304-8.</font></font></li>

        <li><a id="FN227" name="FN227"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Uitto J, Santa
        Cruz DJ, Bauer EA, et al.</b> Morphea and lichen sclerosus
        et atrophicus. J Am Acad Dermatol 1980; 3:
        271-9.</font></font></li>

        <li><a id="FN228" name="FN228"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Curth W, Curth
        HO.</b> Diagnosis: generalized scleroderma or lichen
        sclerosus et atrophicus. Arch Dermatol 1962; 85:
        117-9.</font></font></li>

        <li><a id="FN229" name="FN229"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Witten VH,
        Gelfarb M.</b> Scleroderma: guttate morphea vs. lichen
        sclerosus et atrophicus. Arch Dermatol 1962; 85:
        546-8.</font></font></li>

        <li><a id="FN230" name="FN230"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pierard GE,
        Arrese-Estrada J, Pierard-Franchimont C, et al.</b> Is
        there a link between dendrocytes, fibrosis, and sclerosis?
        Dermatologica 1990; 181: 264-5.</font></font></li>

        <li><a id="FN231" name="FN231"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lewis GM.</b>
        Scleroderma: Lichen sclerosus et atrophicus? Arch Dermatol
        1961; 84: 146-8.</font></font></li>

        <li><a id="FN232" name="FN232"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Buechner SA,
        Winkelmann RK, Lautenschlager S, et al.</b> Localized
        scleroderma assocaited with <i>Borrelia burgdorferi</i>
        infection. J Am Acad Dermatol 1993; 29:
        190-6.</font></font></li>

        <li><a id="FN233" name="FN233"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Aberer E,
        Kollegger H, Kristoferitsch W, et al.</b> Neuroborreliosis
        in morphea and lichen sclerosus et atrophicus. J Am Acad
        Dermatol 1988; 19: 820-5.</font></font></li>

        <li><a id="FN234" name="FN234"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Abele DC, Anders
        KH.</b> The many faces of phases of borreliosis II. J Am
        Acad Dermatol 1990; 23: 401-10.</font></font></li>

        <li><a id="FN235" name="FN235"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Montgomery H,
        Sullivan RR.</b> Acrodermatitis atrophicans chronica. Arch
        Dermatol Syph 1945; 51: 32-47.</font></font></li>

        <li><a id="FN236" name="FN236"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Asbrink E,
        Brehmer-Andersson E, Hovmark A.</b> Acrodermatitis chronica
        atrophicans: a spirochetosis. Am J Dermatopathol 1986; 8:
        209-19.</font></font></li>

        <li><a id="FN237" name="FN237"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Irvine HG.</b>
        Idiopathic atrophy of the skin. JAMA 1913; 61:
        396-400.</font></font></li>

        <li><a id="FN238" name="FN238"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Senear FE.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1948;
        58: 540.</font></font></li>

        <li><a id="FN239" name="FN239"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Goodman MH.</b>
        Circumscribed scleroderma [Comment]. Arch Dermatol Syph
        1939; 39: 904-7.</font></font></li>

        <li><a id="FN240" name="FN240"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Chorzelski T,
        Jablonska S.</b> Coexistence of lupus erythematosus and
        scleroderma in light of immunopathological investigations.
        Acta Derm Venereol (Stockh) 1970; 50:
        81-5.</font></font></li>

        <li><a id="FN241" name="FN241"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Shono S, Imura M,
        Ota M, et al.</b> Lichen sclerosus et atrophicus, morphea,
        and coexistence of both diseases. Arch Dermatol 1991; 127:
        1352-6.</font></font></li>

        <li><a id="FN242" name="FN242"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Panizzon R,
        Vuorio T, Bruckner-Tuderman L.</b> Collagen biosynthesis
        and type I and type III procollagen mRNA in lichen
        sclerosus et atrophicus. Arch Dermatol Res 1990; 282:
        480-3.</font></font></li>

        <li><a id="FN243" name="FN243"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Goltz R, Pinkus
        H, Winklemann RK, et al.</b> Questions to the editorial
        board and other authorities. Am J Dermatolpathol 1980; 2:
        283-6.</font></font></li>

        <li><a id="FN244" name="FN244"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Oikarinen A,
        Sandberg M, Hurskainen T, et al.</b> Collagen biosynthesis
        in lichen sclerosus et atrophicus studied by biochemical
        and in situ hybridization techniques. Acta Derm Venereol
        (Stockh) 1991; 16: 3-12.</font></font></li>

        <li><a id="FN245" name="FN245"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Patterson JAK,
        Ackerman AB.</b> Lichen sclerosus et atrophicus is not
        related to morphea. Am J Dermatopathol 1984; 6:
        323-35.</font></font></li>

        <li><a id="FN246" name="FN246"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tremaine RDL,
        Miller RA.</b> Lichen sclerosus et atrophicus. Int J
        Dermatol 1989; 28: 10-6.</font></font></li>

        <li><a id="FN247" name="FN247"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Nomland R.</b>
        Lichen sclerosus et atrophicus (Hallopeau) and related
        cutaneous atrophies. Arch Dermatol Syph 1930; 21P:
        575-94.</font></font></li>

        <li><a id="FN248" name="FN248"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Murphy FR, Lipa
        M, Haberman HF.</b> Familial vulvar dystrophy of lichen
        sclerosus type. Arch Dermatol 1982; 118:
        329-31.</font></font></li>

        <li><a id="FN249" name="FN249"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Black MM.</b> The association of lichen
        sclerosus et atrophicus and autoimmune-related disease in
        males. Br J Dermatol 1983; 109: 661-4.</font></font></li>

        <li><a id="FN250" name="FN250"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Goolamali SK,
        Barnes EW, Irvine WJ, et al.</b> Organ-specific antibodies
        in patients with lichen sclerosus. Br Med J 1974; 4:
        78-9.</font></font></li>

        <li><a id="FN251" name="FN251"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cunliffe WJ,
        Newell DJ, Hall R, et al.</b> Vitiligo, thyroid disease,
        and autoimmunity. Br J Dermatol 1968; 80:
        135-9.</font></font></li>

        <li><a id="FN252" name="FN252"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Faergemann J.</b>
        Lichen sclerosus et atrophicus generalisata, alopecia
        areata, and polymyalgia rheumatica found in the same
        patient. Cutis 1979; 23: 757-8.</font></font></li>

        <li><a id="FN253" name="FN253"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Williams GA,
        Richardson AC, Hatchcock EW.</b> Topical testosterone in
        dystrophic diseases of the vulva. Am J Obstet Gynecol 1966;
        96: 21-30.</font></font></li>

        <li><a id="FN254" name="FN254"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ayhan A, Urman B,
        Yuece K, et al.</b> Topical testotosterone for lichen
        sclerosus. Int J Gynaecol Obstet 1989; 30:
        253-5.</font></font></li>

        <li><a id="FN255" name="FN255"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Poskitt L,
        Wojnarowska F.</b> Lichen sclerosus as a cutaneous
        manifestation of thyroid disease [Letter]. J Am Acad
        Dermatol 1993; 28: 665.</font></font></li>

        <li><a id="FN256" name="FN256"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Aberer E, Neumann
        R, Lubec G.</b> Acrodermatitis chronica atrophicans in
        association with lichen sclerosus et atrophicans:
        tubulo-intersititial nephritis and urinary excretion of
        spirochete-like organisms. Acta Derm Venereol (Stockh)
        1987; 67: 62-5.</font></font></li>

        <li><a id="FN257" name="FN257"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Winkelmann RK,
        Connolly Sm, Doyle JA.</b> Carpal tunnel syndrome in
        cutaneous connective tissue disease: generalized morphea,
        lichen sclerosus, fasciitis, discoid lupus erythematosus,
        and lupus panniculitus. J Am Acad Dermatol 1982; 7:
        94-9.</font></font></li>

        <li><a id="FN258" name="FN258"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Graham-Brown RAC,
        Sarkany I.</b> Lichen sclerosus et atrophicus. Int J
        Dermatol 1986; 25: 317.</font></font></li>

        <li><a id="FN259" name="FN259"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lavery HA,
        Pinkerton JHM, Callender M.</b> The association of lichen
        sclerosus et atrophicus and primary biliary cirrhosis
        [Letter]. Br J Dermatol 1985; 112:
        729-30.</font></font></li>

        <li><a id="FN260" name="FN260"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lynch FW,
        Montgomery H, Brunstig LA.</b> Morphea, lichen sclerosus et
        atrophicus, alopeacia areata, vitiligo. Arch Dermatol 1962;
        85: 681-2.</font></font></li>

        <li><a id="FN261" name="FN261"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Sloan PJM, Goepel
        J.</b> Lichen sclerosus et atrophicus and perianal
        carcinoma: a case report. Clin Exp Dermatol 1981; 6:
        399-402.</font></font></li>

        <li><a id="FN262" name="FN262"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bor S, Feiwel M,
        Chanarin I.</b> Vitiligo and its aetiological relationship
        to organi-specific autoimmune disease. Br J Dermatol 1969;
        81: 83-8.</font></font></li>

        <li><a id="FN263" name="FN263"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Harrington CI,
        Dunsmore IR.</b> An investigation into the incidence of
        auto-immune disorders in patients with lichen sclerosus and
        atrophicus. Br J Dermatol 1981; 104:
        653-6.</font></font></li>

        <li><a id="FN264" name="FN264"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lavery HA,
        Pinkerton JHM, Callendar M.</b> Association between lichen
        sclerosus et atrophicus and primary biliary cirrhosis
        [Letter]. Br J Dermatol 1986; 114: 515.</font></font></li>

        <li><a id="FN265" name="FN265"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Black MM.</b> The association between lichen
        sclerosus et atrophicus and autoimmune disease in males: an
        addendum [Letter]. Br J Dermatol 1984; 111:
        371-2.</font></font></li>

        <li><a id="FN266" name="FN266"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Ridley CM, Black MM.</b> The association between lichen
        sclerosus et atrophicus and auto-immune diseases in males
        is not proven [Letter]. Br J Dermatol 1984; 111:
        122.</font></font></li>

        <li><a id="FN267" name="FN267"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bushkell LL,
        Friedrich EG, Jordon RE.</b> An appraisal of routine direct
        immunofluorescence in vulvar disorders. Acta Derm Venereol
        (Stockh) 1981; 61: 157-61.</font></font></li>

        <li><a id="FN268" name="FN268"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dickie RJ, Horne
        CHW, Sutherland HW, et al.</b> Direct evidence of localised
        immunological damage in vulvar lichen sclerosus et
        atrophicus [Letter]. J Clin Pathol 1982; 35:
        1395-7.</font></font></li>

        <li><a id="FN269" name="FN269"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Carli P, Cattaneo
        A, Pimpinelli N, et al.</b> Immunohistochemical evidence of
        skin immune system involvement in vulvar lichen sclerosus
        et atrophicus. Dermatologica 1991; 182:
        18-22.</font></font></li>

        <li><a id="FN270" name="FN270"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Holmes RC, Rowland Payne CME, et al.</b> The incidence of
        development of autoimmune diseases in women after diagnosis
        of lichen sclerosus et atrophicus [Abstract]. Br J Dermatol
        1982; 107 (suppl 22): 29.</font></font></li>

        <li><a id="FN271" name="FN271"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kahana M, Levy A,
        Schewach-Millet M, et al.</b> Lichen sclerosus et
        atrophicus assocaited with systemic lupus erythematosus
        [Letter]. J Am Acad Dermatol 1985; 13:
        832-3.</font></font></li>

        <li><a id="FN272" name="FN272"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Curth HO.</b>
        Lichen sclerosus et atrophicus [Comment]. Arch Dermatol
        1973; 108: 433.</font></font></li>

        <li><a id="FN273" name="FN273"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Thomas RHM,
        Kennedy CT.</b> The development of lichen sclerosus et
        atrophicus in monozygotic twin girls. Br J Dermatol 1986;
        114: 277-9.</font></font></li>

        <li><a id="FN274" name="FN274"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cox NH, Mitchell
        JNS, Morley Wn.</b> Lichen sclerosus et atrophicus in
        non-identical female twins [Letter]. Br J Dermatol 1986;
        115: 743-6.</font></font></li>

        <li><a id="FN275" name="FN275"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Holt PJA, Darke
        C.</b> HLA antigens in lichen sclerosus et atrophicus
        [Letter]. Clin Exp Dermatol 1985; 10:
        182-3.</font></font></li>

        <li><a id="FN276" name="FN276"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Harrington CI,
        Gelsthorpe K.</b> The association between lichen sclerosus
        et atrophicus and HLA-B40. Br J Dermatol 1981; 104:
        561-2.</font></font></li>

        <li><a id="FN277" name="FN277"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Holt PJA, Darke
        C.</b> HLA antigens and Bf allotypes in lichen sclerosus et
        atrophicus. Tissue Antigens 1983; 22:
        89-91.</font></font></li>

        <li><a id="FN278" name="FN278"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Sideri M, Rognoni
        M, Rizzolo L, et al.</b> Antigens of the HLA system in
        women with vulvar lichen sclerosus. J Reprod Med 1988; 33:
        551-3.</font></font></li>

        <li><a id="FN279" name="FN279"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Purcell KG,
        Spencer LV, Simpson PM, et al.</b> HLA antigens in lichen
        sclerosus et atrophicus. Arch Dermatol 1990; 126:
        1043-5.</font></font></li>

        <li><a id="FN280" name="FN280"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Daunt SO,
        Kotowski KE, Reilly AP, et al.</b> Ulcerative vulvitis in
        Reiter's syndrome. Br J Vener Dis 1982; 58:
        405-7.</font></font></li>

        <li><a id="FN281" name="FN281"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hazen HH.</b> An
        anomalous case of white-spot disease. JAMA 1913; 61:
        393-6.</font></font></li>

        <li><a id="FN282" name="FN282"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Brain RT.</b>
        Lichen sclerosus et atrophicus. Br J Dermatol 1950; 62:
        449-51.</font></font></li>

        <li><a id="FN283" name="FN283"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Needleman BW,
        Ordonex JV, Taramelli D, et al.</b> In vitro identification
        of a subpopulation of fibroblasts that produces high levels
        of collagen in scleroderma patients. Arthritis Rheum 1990;
        33: 842-52.</font></font></li>

        <li><a id="FN284" name="FN284"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Botsetin GR,
        Scherer GK, Leroy EC.</b> Fibroblast selection in
        scleroderma. Arthritis Rheum 1982; 25:
        189-95.</font></font></li>

        <li><a id="FN285" name="FN285"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cantwell AR.</b>
        Histologic forms resembling "large bodies" in scleroderma
        and "pseudoscleroderma." Am J Dermatopathol 1980; 2:
        272-6.</font></font></li>

        <li><a id="FN286" name="FN286"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cantwell AR.</b>
        Histologic observations of pleomorphic, variably acid-fast
        bacteria in scleroderma, morphea, and lichen sclerosus et
        atrophicus. Int J Dermatol 1984; 23:
        45-52.</font></font></li>

        <li><a id="FN287" name="FN287"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Sherwell S.</b> A
        case of white spot disease. J Cutan Dis 1904; 22:
        188-9.</font></font></li>

        <li><a id="FN288" name="FN288"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Stanek G, Wewalka
        G, Groh V, et al.</b> Differences between Lyme disease and
        European arthropod-borne <i>Borrelia</i> infections. Lancet
        1985; 1: 401.</font></font></li>

        <li><a id="FN289" name="FN289"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ross SA,
        S&aacute;nchez JL, Taboas JO.</b> Spirochetal forms in the
        dermal lesions of morphea and lichen sclerosus et
        atrophicus. Am J Dermatopathol 1990; 12:
        357-62.</font></font></li>

        <li><a id="FN290" name="FN290"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Aberer E, Stanek
        G.</b> Histological evidence for spirochetal origin of
        morphea and lichen sclerosus atrophicans. Am J
        Dermatopathol 1987; 9: 374-9.</font></font></li>

        <li><a id="FN291" name="FN291"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tuffanelli D.</b>
        Do some patients with morphea and lichen sclerosus et
        atrophicans have a borrelia infection? Am J Dermatopathol
        1987; 9: 371-3.</font></font></li>

        <li><a id="FN292" name="FN292"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Koff AB, Rosen
        T.</b> Nonvenereal terponematoses: yaws, endemic syphilis,
        and pinta. J Am Acad Dermatol 1993; 29:
        519-35.</font></font></li>

        <li><a id="FN293" name="FN293"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Habicht GS, Beck
        ZG, Benach JL, et al.</b> Lyme disease spirochetes induce
        human and murine interleukin 1 production. J Immunol 1985;
        134: 147-54.</font></font></li>

        <li><a id="FN294" name="FN294"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Stuart JM,
        Postelwaite AE, Kang AH.</b> Evidence for cell-mediated
        immunity to collagen in progressive systemic sclerosis. J
        Lab Clin Med 1976; 88: 601-7.</font></font></li>

        <li><a id="FN295" name="FN295"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kravis TC, Ahmed
        A, Brown TE, et al.</b> Pathogenic mechanisms in pulmonary
        fibrosis. J Clin Invest 1976; 58:
        1223-32.</font></font></li>

        <li><a id="FN296" name="FN296"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Persson U,
        M&ouml;ller G.</b> Effect of polyclonal B-cell activators
        on DNA synthesis in fibroblasts. Scand J Immunol 1965; 4:
        527-34.</font></font></li>

        <li><a id="FN297" name="FN297"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Uitto J, Bauer
        EA, Eisen AZ.</b> Increased biosynthesis of triple-helical
        type I and type III procollagens associated with unaltered
        expression of collagenase by skin fibroblasts in culture. J
        Clin Invest 1979; 64: 921-30.</font></font></li>

        <li><a id="FN298" name="FN298"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Panizzon R,
        Tuderman L, Vuorio T.</b> Decreased collagen biosynthesis
        and unchanged procollagen-mRNA type I and type III levels
        in fibroblasts from lesional foreskin of 3 patients with
        lichen sclerosus et atrophicus [Abstract]. J Invest
        Dermatol 1986; 87: 161.</font></font></li>

        <li><a id="FN299" name="FN299"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Godeau G, Frances
        C, Hornebeck W, et al.</b> Isolation and partial
        characterization of an elastase-type protease in human
        vulva fibroblasts: its possible involvement with lichen
        sclerosus et atrophicus. J Invest Dermatol, 1982; 78:
        270-5.</font></font></li>

        <li><a id="FN300" name="FN300"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Nelson DL, Balian
        G.</b> The influence of retinoic acid on collagen synthesis
        by skin fibroblasts [Abstract]. J Invest Dermatol 1983; 80:
        357.</font></font></li>

        <li><a id="FN301" name="FN301"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Davidson EA,
        Small W.</b> Metabolism in vivo of connective-tissue
        mucopolysaccharides II. Biochum Biophys Acta 1963; 69:
        453-8.</font></font></li>

        <li><a id="FN302" name="FN302"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman M,
        Straisfield C, Pinksy L.</b> Expression of
        androgen-responsive properties in human skin fibroblast
        strains of genital and nongenital origin. Somat Cell Genet
        1977; 3: 17-25.</font></font></li>

        <li><a id="FN303" name="FN303"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG,
        Kalra PS.</b> Serum levels of sex hormones in vulvar lichen
        sclerosus and the effect of topical testosterone. N Engl J
        Med 1984; 308: 488-91.</font></font></li>

        <li><a id="FN304" name="FN304"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Strauss JS, Pochi
        PE.</b> Recent advances in androgen metabolism and their
        relation to the skin. Arch Dermatol 1969; 100:
        621-36.</font></font></li>

        <li><a id="FN305" name="FN305"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Meyer WJ, Migeon
        BR, Migeon CJ.</b> Locus on human X chromosome for
        dihydrotestosterone recpetor and androgen sensitivity. Proc
        Natl Acad Sci USA 1975; 72: 1469-72.</font></font></li>

        <li><a id="FN306" name="FN306"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Sideri M,
        Parazzini F, Rognoni MT, et al.</b> Risk factors for vulvar
        lichen sclerosus. Am J Obstet Gynecol 1989; 161:
        38-42.</font></font></li>

        <li><a id="FN307" name="FN307"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cummer CL.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1946;
        54: 629.</font></font></li>

        <li><a id="FN308" name="FN308"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hunt E.</b>
        Diseases affecting the vulva. 4th ed. St Louis: CV Mosby,
        1954: 92-9, 208.</font></font></li>

        <li><a id="FN309" name="FN309"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Falk AB,
        Bielinski S.</b> Lichen sclerosus et atrophicus. Arch
        Dermatol 1964; 89: 619-20.</font></font></li>

        <li><a id="FN310" name="FN310"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Schoch EP,
        McQuiston CH.</b> Diagnostic and therapeutic errors in
        certain dermatoses of the vulva. JAMA 1955; 157:
        1102-6.</font></font></li>

        <li><a id="FN311" name="FN311"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kaufman RH,
        Friedrich EG.</b> The carbon dioxide laser in the treatment
        of vulvar disease. Clin Obstet Gynecol 1985; 28:
        220-9.</font></font></li>

        <li><a id="FN312" name="FN312"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ratz JL.</b> <a
        href="/library/treatment/BXO/ratz1/">Carbon dioxide laser
        treatment of balanitis xerotica obliterans</a>. J Am Acad
        Dermatol 1984; 10: 925-8.</font></font></li>

        <li><a id="FN313" name="FN313"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rosenberg SK,
        Jacobs H.</b> Continuous wave carbon dioxide treatment of
        balanitis xerotica obliterans. Urology 1982; 19:
        539-41.</font></font></li>

        <li><a id="FN314" name="FN314"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mitchell JH.</b>
        Lichen planus atrophicus. Arch Dermatol Syph 1929; 19:
        143.</font></font></li>

        <li><a id="FN315" name="FN315"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ginsburg L.</b>
        Circumscribed scleroderma (white spot disease). Arch
        Dermatol Syph 1939: 39: 903-4.</font></font></li>

        <li><a id="FN316" name="FN316"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Feldman FF,
        Lerner AG.</b> Bullous lichen sclerosus et atrophicus. Arch
        Dermatol 1961; 83: 705-6.</font></font></li>

        <li><a id="FN317" name="FN317"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cummer CL.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1944;
        49: 449.</font></font></li>

        <li><a id="FN318" name="FN318"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Turell R.</b>
        Tattooing with mercuric sulfide for the treatment of
        intractable pruritis vulvae and ani. Am J Obstet Gynecol
        1941; 42: 290-6.</font></font></li>

        <li><a id="FN319" name="FN319"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Dobes WL.</b>
        Lichen sclerosus et atrophicus of the female genitalia
        [Comment]. Arch Dermatol 1962; 85:
        372-3.</font></font></li>

        <li><a id="FN320" name="FN320"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ward GD,
        Suthherst JR.</b> Pruritis vulvae: treatment by multiple
        intradermal alcohol injections. Br J Dermatol 1975; 93:
        201-4.</font></font></li>

        <li><a id="FN321" name="FN321"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Woodruff JD,
        Thompson B.</b> Local alcohol injection in the treatment of
        vulvar pruritis. Obstet Gynecol 1972; 40:
        18-22.</font></font></li>

        <li><a id="FN322" name="FN322"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ridley CM.</b>
        The vulva. London: WB Saunders, 1975:
        172-85.</font></font></li>

        <li><a id="FN323" name="FN323"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bergfield WF,
        Lesowitz SA.</b> Lichen sclerosus et atrophicus. Arch
        Dermatol 1970; 101: 247-8.</font></font></li>

        <li><a id="FN324" name="FN324"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Scully JP.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol 1958; 77:
        763.</font></font></li>

        <li><a id="FN325" name="FN325"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Everett MA,
        Coffey CM.</b> Intradermal administration of chloroquine.
        Arch Dermatol 1961; 83: 131-3.</font></font></li>

        <li><a id="FN326" name="FN326"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Coskey RJ.</b>
        Dermatologic therapy: December 1983 through November 1984.
        J Am Acad Dermatol 1985; 12: 1045-71.</font></font></li>

        <li><a id="FN327" name="FN327"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Bergman A, Karram
        M, Bhatia NN.</b> Local steroid application for
        hyperplastic dystrophy of the vulva. J Reprod Med 1988; 33:
        542-4.</font></font></li>

        <li><a id="FN328" name="FN328"></a><font
        face="Arial,Helvetica"><font size="-1"><b>McKay M.</b>
        Vulvodynia versus pruritis vulvae. Clin Obstet Gynecol
        1985; 28: 123-33.</font></font></li>

        <li><a id="FN329" name="FN329"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mering JH.</b> A
        surgical approach to intractable pruritis vulvae. Am J
        Obstet Gynecol 1952; 64: 619-27.</font></font></li>

        <li><a id="FN330" name="FN330"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Mering JH.</b>
        Some further observations on wide skin undercutting for
        intractable pruritis vuvlae. Am J Obstet Gynecol 1956; 71:
        386-90.</font></font></li>

        <li><a id="FN331" name="FN331"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Crow KD, Ellis J,
        Wynne EJC.</b> Lichen sclerosus et atrophicus of the penis.
        Br J Dermatol 1980; 103 (suppl 18): 17.</font></font></li>

        <li><a id="FN332" name="FN332"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Glickman FS,
        Silvers SH.</b> Generalized bullous and hemorrhagic lichen
        sclerosus et atrophicus. Cutis 1972; 10:
        501-3.</font></font></li>

        <li><a id="FN333" name="FN333"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Stritzler C.</b>
        Lichen sclerosus et atrophicans. Arch Dermatol 1961; 83:
        1028.</font></font></li>

        <li><a id="FN334" name="FN334"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pillsbury DM,
        Shelley WB.</b> Intradermal steroid therapy. Arch Dermatol
        1963; 87: 338-9.</font></font></li>

        <li><a id="FN335" name="FN335"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Poynter JH, Levy
        J.</b> Balanitis xerotica obliterans: effective treatment
        with topical and sublesional corticosteroids. Br J Urol
        1967; 39: 420-5.</font></font></li>

        <li><a id="FN336" name="FN336"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cole HN.</b>
        Balanitis xerotica obliterans [Comment]. Arch Dermatol Syph
        1941; 44: 560.</font></font></li>

        <li><a id="FN337" name="FN337"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Richardson AC,
        Williams GA.</b> Topical androgenic hormones in vulvar
        kraurosis-leukoplakia syndrome. Am J Obstet Gyencol 1958;
        76: 791-9.</font></font></li>

        <li><a id="FN338" name="FN338"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Zelle K.</b>
        Treatment of vulvar dystrophies with topical testosterone
        proprionate. Am J Obstet Gynecol 1971; 109:
        570-3.</font></font></li>

        <li><a id="FN339" name="FN339"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cascano EF,
        Montes LF, Mazzini MA.</b> Tissue changes in lichen
        sclerosus in children following local application of
        oestrogens. Br J Dermatol 1964; 76:
        496-7.</font></font></li>

        <li><a id="FN340" name="FN340"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Friedrich EG.</b>
        Topical testosterone for benign vulvar dystrophy. Obstet
        Gynecol 1971; 37: 677-86.</font></font></li>

        <li><a id="FN341" name="FN341"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Cinberg BL.</b>
        Postmenopausal pruritis vulvae. Am J Obstet Gynecol 1945;
        49: 647-57.</font></font></li>

        <li><a id="FN342" name="FN342"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Flynt J, Gallup
        DG.</b> Childhood lichen sclerosus. Obstet Gynecol 1979; 53
        (suppl): 79S-81S.</font></font></li>

        <li><a id="FN343" name="FN343"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rompannen U.</b>
        Long-term results of etretinate therapy in vulvar
        dystrophy. Curr Ther Res 1986; 40:
        442-7.</font></font></li>

        <li><a id="FN344" name="FN344"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jasionowski EA,
        Jasionowski P.</b> Topical progesterone in treatment of
        vulvar dystrophy. Am J Obstet Gynecol 1977; 127:
        667-70.</font></font></li>

        <li><a id="FN345" name="FN345"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Jasionowski EA,
        Jasionowski PA.</b> Further observations on the effect of
        topical progesterone on vulvar disease. Am J Obstet Gynecol
        1979; 134: 565-7.</font></font></li>

        <li><a id="FN346" name="FN346"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Brodey A.</b>
        Hemorrhagic and bullous lichen sclerosus et atrophicus.
        Arch Dermatol 1967; 95: 328-9.</font></font></li>

        <li><a id="FN347" name="FN347"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hesseltine
        HC.</b> Vitamin therapies in vulvar dermatoses. Am J Obstet
        Gynecol 1941; 42: 702-13.</font></font></li>

        <li><a id="FN348" name="FN348"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Pascher F,
        Sawicky HH, Silverberg MG, et al.</b> Tocopherols (Vit E)
        for discoid lupus erythematosus and other dermatoses. J
        Invest Dermatol 1951; 17: 261-6.</font></font></li>

        <li><a id="FN349" name="FN349"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Swift BH.</b>
        Achlorhydria as an aetiological factor in pruritis vulvae
        associated with kraurosis or leucoplakia. J Obstet Gynecol
        Br Emp 1936; 43: 1053-77.</font></font></li>

        <li><a id="FN350" name="FN350"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hyams MN.</b>
        Leukoplakia of the vulva [Comment]. Am J Obstet Gynecol
        1947; 54: 558.</font></font></li>

        <li><a id="FN351" name="FN351"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Post CF, Jewell
        EW.</b> Lichen sclerosus et atrophicus. Arch Dermatol 1960;
        82: 128.</font></font></li>

        <li><a id="FN352" name="FN352"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hyams MN, Bloom
        OH.</b> Leukoplakia vulvae. Am J Obstet Gynecol 1947; 53:
        214-20.</font></font></li>

        <li><a id="FN353" name="FN353"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Klauder JV.</b>
        Lichen sclerosus et atrophicus of the female genitalia
        [Comment]. Arch Dermatol 1962; 85: 373.</font></font></li>

        <li><a id="FN354" name="FN354"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Neuhofer J,
        Fritsch P.</b> Treatment of localized scleroderma and
        lichen sclerosus with etretinate. Acta Derm Venereol
        (Stockh) 1984; 64: 171-4.</font></font></li>

        <li><a id="FN355" name="FN355"></a><font
        face="Arial,Helvetica"><font size="-1"><b>M&oslash;rk N,
        Jensen P, Hoel PS.</b> Vulval lichen sclerosus et
        atrophicus treated with estretinate
        (Tigason</font><sup><font size="-2">&reg;</font></sup><font
        size="-1">). Acta Derm Venereol (Stockh) 1986; 66:
        363-5.</font></font></li>

        <li><a id="FN356" name="FN356"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Minim&auml;ki X,
        Kallioinen M, Oikarinen A.</b> Etretinate reduces
        connective tissue degeneration in lichen sclerosus et
        atrophicus. Acta Derm Venereol (Stockh) 1989; 69:
        439-42.</font></font></li>

        <li><a id="FN357" name="FN357"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rompannen U,
        Tuimala R, Ellm&eacute;n J, et al.</b> Treatment of
        dystrophic changes of the vulva with etretinate or placebo.
        Curr Ther Res 1987; 42; 211-8.</font></font></li>

        <li><a id="FN358" name="FN358"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Crocker.</b>
        Lichen planus: its variations, relations, and imitations.
        Br J Dermatol 1900; 12: 421.</font></font></li>

        <li><a id="FN359" name="FN359"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Kyrle J.</b>
        Histo-biologie der menschichen haut und ihrer erkrankungen.
        Wien: Verlag von Julius Springer, 1927:
        140-1.</font></font></li>

        <li><a id="FN360" name="FN360"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Foerster HR.</b>
        Balanitis xerotica obliterans [Comment]. Arch Dermatol Syph
        1941; 44: 559-60.</font></font></li>

        <li><a id="FN361" name="FN361"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Brain RT, Haber
        H.</b> Lichen sclerosus et atrophicus. Br J Dermatol 1950;
        62: 170-1.</font></font></li>

        <li><a id="FN362" name="FN362"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Skeer J.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1941;
        44: 530-1.</font></font></li>

        <li><a id="FN363" name="FN363"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Hubler WR.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1946;
        54: 628-9.</font></font></li>

        <li><a id="FN364" name="FN364"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Rothran S, Farney
        Davies E.</b> Lichen sclerosus et atrophicus. Arch Dermatol
        Syph 1951; 64: 653-4.</font></font></li>

        <li><a id="FN365" name="FN365"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Ebert MH.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol Syph 1951;
        64: 654-5.</font></font></li>

        <li><a id="FN366" name="FN366"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Lawrence WD.</b>
        Lichen sclerosus et atrophicus of the vulva. Obstet Gynecol
        1959; 14: 65-7.</font></font></li>

        <li><a id="FN367" name="FN367"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Abrahams I.</b>
        Lichen sclerosus et atrophicus. Arch Dermatol 1973; 108:
        433.</font></font></li>

        <li><a id="FN368" name="FN368"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Svendsen IB.</b>
        Lichen sclerosus et atrophicus of the anogenital region in
        a girl aged 4 years. Acta Derm Venereol (Stockh) 1954; 34:
        321-9.</font></font></li>

        <li><a id="FN369" name="FN369"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Oliver EA,
        Finnerud X.</b> Lichen planus sclerosus et atrophicus. Arch
        Dermatol Syph 1929; 19: 829.</font></font></li>

        <li><a id="FN370" name="FN370"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Fleisher Tl,
        Zeligman I.</b> Cutaneous findings in phenylketonuria. Arch
        Dermatol 1960; 81: 898-903.</font></font></li>

        <li><a id="FN371" name="FN371"></a><font
        face="Arial,Helvetica"><font size="-1"><b>de Oliviera JM,
        Saleiro V.</b> Involucrin expression in vulvar lesions. J
        Reprod Med 1986; 31: 828-30.</font></font></li>

        <li><a id="FN372" name="FN372"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Yoshima H,
        Shinkai H, Shigeharu S, et al.</b> Acidic
        glycosaminoglycans in skin and urine of a patient with wide
        spreaded [sic] lichen sclerosus et atrophicus. Arch
        Dermatol Res 1978; 263: 59-66.</font></font></li>

        <li><a id="FN373" name="FN373"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Anderson CR.</b>
        Bullous lichen sclerosus et atrophicus. Arch Dermatol Syph
        1944; 49: 423-6.</font></font></li>

        <li><a id="FN374" name="FN374"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Tompkins KJ,
        James WD.</b> Persistent bullae on the penis of an elderly
        man. Arch Dermatol 1987; 123: 1391-6.</font></font></li>

        <li><a id="FN375" name="FN375"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Buchanan JD,
        Catterall MD, Briggs PC.</b> Posthitis xertoica obliterans.
        J R Nav Med Serv 1979; 65: 136-9.</font></font></li>

        <li><a id="FN376" name="FN376"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Di Paola GR.</b>
        The problem of so-called cancerous lesions of the vulva:
        ten years of prospective experience. Eur J Gynaec Oncol
        1980; 1: 20-8.</font></font></li>

        <li><a id="FN377" name="FN377"></a><font
        face="Arial,Helvetica"><font size="-1"><b>Miller NF, Riley
        GM, Stanley M.</b> Leukoplakia of the vulva. Am J Obstet
        Gynecol 1952; 64: 768-79.</font></font></li>
      </ol>
      <br />
    </div>
    <hr />

    Citation:
    <ul>
      <li>Meffert JJ, Davis BM, Grimwood RE. Lichen Sclerosus. <i>J
      Am Acad Dermatol</i> 1995;32(3): 393-416.</li>
    </ul>
    <hr />
    <small>(File revised 26 June 2005)</small> 

    <center>
      <p class="navlink"><a href="/library/">Return to CIRP
      Library</a></p>
    </center>

    <p>
    <tt>http://www.cirp.org/library/treatment/BXO/meffert1/</tt></p>
  </body>
</html>
